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ABSTRACT
Identification and Characterization of Serum Biomarkers
Associated with Breast Cancer Progression
Adhari Abdullah Al Zaabi
Department of Physiology and Develomental Biology, BYU
Doctor of Philosophy
Despite the recognized advances in the treatment of breast cancer, it still accounts
for 15% of all cancer-related deaths. 90% of breast cancer deaths are due to unpredicted
metastasis. There is neither successful treatment for metastatic patients nor a specific test
to predict or detect secondary lesions. Patients with primary tumor will be either overtreated with cytotoxic side effects or under-treated and risk recurrence. This necessitates
the need for personalized treatment, which is hard to offer for such heterogeneous disease.
Obstacles in treating breast cancer metastasis are mainly due to the gaps exist in the understanding of the molecular mechanism of metastasis. The linear model of metastasis
is supported by several observations that reflect an early crosstalk between the primary
and secondary tumor, which in turn makes the secondary microenvironment fertile for the
growth of disseminated cells. This communication occurs through circulation and utilizes
molecules which have not been identified to date. Identifying such molecules may help in
detecting initial stages of tumor colonization and predict the target organ of metastasis.
Furthermore, these molecules may help to provide a personalized therapy that aims
to tailor treatment according to the biology of the individual tumor. Advances in proteomics allows for more reproducible and sensitive biomarker discovery. Proteomic biomarkers are often more translatable to the clinic compared to biomarkers identified using other
omics approaches. Further, protein biomarkers can be found in biological fluids making
them a non-invasive way to treat or investigate cancer patients. We present in this manuscript
our study of the use of a proteomic approach on blood serum samples of metastatic and
non-metastatic patients using LC-MS/MS quantitative analysis machine to identify molecules
that could be associated with different stages of breast cancer metastasis. We focused on
the deferential expression of low molecular weight biomolecules known to reflect diseasespecific signatures. We manually analyzed 2500 individual small biomolecules in each serum
sample of total of 51 samples. Comparisons between different sample types (from stage I
and III Breast Cancer patients in this case) allows for the detection of unique short peptide biomarkers present in one sample type. We built a multi-biomarker model with more
sensitivity and specificity to identify the stage of the tumor and applied them on blinded
set of samples to validate prediction power. We hope that our study will provide insights
for future work on the collection, analysis, and understanding of role of molecules in metastatic
breast cancer.

Keywords: breast cancer, metastasis, low-molecular weight, serum peptidome, biomarkers,
multimarker model, cLC-MS/MS
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CHAPTER 1: Introduction and Background

Cancer Metastasis
Cancer is considered the second leading cause of death in the united state after
heart diseases. It is expected to overtake the heart disease death rate imminently. Approximately, 90% of human cancer deaths are due to metastasis [1]. The survival rate of
almost all cancer types drops dramatically once the tumor disseminates and establish a
secondary growth at distant organs. Therefore, metastasis is considered the most determinant prognostic factor in cancer [1, 2]. The mystery surrounding metastasis makes it hard
to predict, diagnose and treat. Despite all the advancement in early cancer detection and
treatment, metastasis remains a complicated puzzle with no foreseeable solution. The current clinical practice to diagnose and treat metastasis are mainly to prolong patients life as
much as possible regardless of the quality of patients life [3].

Breast Cancer Metastasis
Maymuna is a 35-year old assistant professor of clinical anatomy at the College of
Medicine at Sultan Qaboos University in Oman. She has a happy, social and optimistic
personality. She is a mother of five kids; the youngest is 6 months old. Her life dramatically changed after she has been diagnosed with Breast Cancer. Luckily she was at stage
II and the tumor was positive to estrogen receptor. She was treated according to the guideline, where she underwent surgery and received hormonal therapy with adjuvant chemotherapy. She got back to her normal life after a long period of hospital admission, pain and
chemotherapy-induced side effects. The doctors assured her that she has a very low risk
of relapse or metastasis because of her age, multi-parity, negative family history of tumor
and her hormone sensitive tumor. Unfortunately, a year later, she started to have shortness of breath and high fever. She has been admitted in intensive care unit because of her
rapidly deteriorating health. Within 10 days of these symptoms she passed away due to
1

lung and pleural metastasis leaving a husband and 5 kids with tearful memories. This is
a true story of my friend, who, unfortunately, was not the first nor the last to suffer this
fate. According to the American Cancer Society, one woman in the U.S. will lose her life
to Breast Cancer every 13 minutes [4].
Breast Cancer (BC) is the second leading cause of all cancer deaths among women
worldwide. In the United States, about 40,000 women succumb to Breast Cancer annually. 90% of deaths from Breast Cancer occur in patients with advanced, metastatic disease. Five year survival rates of Breast Cancer patients drop from 99% for women treated
in early stage cancer to 25% for women treated in later stages [5, 6]. Treatment costs increase as the disease progresses and furthermore the intent of treatment becomes more of
controlling the disease as long as possible rather than cure [7].

Diagnosis of Breast Cancer Metastasis
The mystery of Breast Cancer metastasis is that it is unpredictable, can remain
dormant for several decades, and is far less responsive to available cancer therapy [8]. Unfortunately, there is no accurate method to measure or monitor metastatic disease at very
early stages of the metastatic spread. Monitoring of metastatic disease is performed by
time consuming, costly, invasive and complicated radiological studies that suffer from low
sensitivities and specificities [5, 8]. Once suspected, diagnosis of Breast Cancer for local or
distant recurrence is accompanied by invasive, and painful biopsies of the affected organs
[9]. As a result, assessment of whether Breast Cancer patients are at risk for recurrence
due to early metastatic spread or whether treatments have been successful in eliminating residual metastatic disease remain inconclusive and inaccurate. The ability to detect
metastatic disease is a critical driver in whether continued gains in Breast Cancer treatment can be achieved. Therefore, the identification of each individual tumor’s metastatic
potential is required to personalize treatment protocol for each patient [9, 10, 11, 12, 13,
14].

2

Treatment of Breast Cancer Metastasis
Transcriptomic studies divided primary Breast Cancer into five subtypes; Table
1.1 [15]. The most common and least invasive Breast Cancer subtype is the luminal type.
This tumor type expresses estrogen receptors (ER) and usually responds to tamoxefin (an
estrogen receptor inhibitor) and/or aromatase inhibitors with a good prognosis. The second subtype over-expresses human epidermal receptor (HER-2) and behaves more aggressively, but responds well to targeted therapy with trastuzumab, a monoclonal antibody
against HER-2. The third and a more aggressive subtype is the basal subtype, which does
not express any key hormonal receptors. Thus, Breast Cancers of this subtype are referred
to as triple negative tumors for their lack of estrogen, progesterone and HER-2 receptors
[16]. This tumor subtype does not respond to any targeted therapy and therefore needs
a broad spectrum chemotherapy, which has unpleasant short and long term side effects
that impair the patient’s quality of life. Despite reliance on broad spectrum chemotherapy, triple negative breast cancer (TNBC) also has the worst prognosis among all Breast
Cancer subtypes [17, 18].
It is very straightforward to identify subtypes by determining the hormone status
of the patient’s tumor and thus predict the patient’s prognosis and response to treatment.
However, in the real world, scenarios are completely different. Breast Cancer patients with
identical tumor histopathology will respond differently to the same treatment. This can be
explained by the molecular heterogeneity between the tumors that challenges development
of personalized therapy for Breast Cancer [19, 20, 21].
Despite the use of tamoxefin and trastuzumab which are considered as targeted
treatment, American society of Clinical Oncology (ASCO) latest recommendation is to
use adjuvant chemotherapy as a precaution to eradicate escaped tumor cells, even if undetectable, and thus reduce risk of recurrence. This is because tumor aggressiveness cannot be easily assessed and there is currently no test that can evaluate patient’s risk of local or distant recurrence. It has been estimated that almost 80% of primary BC patients
3

are receiving adjuvant therapy although 50% of those patient will never get progressed to
an advance stage and they will benefit from local treatment alone [3]. Metastatic lesions,
when identified, are usually not treated by surgical resection, but rather by a more systemic therapy. This is because the presence of a metastatic lesions often indicate a more
systemic disease that needs to be attacked [21].

Prognostic Indicators of Metastatic Breast Cancer
Every Breast Cancer patient will be evaluated comprehensively to determine her
metastatic risk and whether she requires for only local or more aggressive systemic therapy. The prognostic factors that are currently used are mainly clinicopathological parameters, such as patient’s age at diagnosis, lymph node status, grade of malignancy, and hormone receptor status by focusing on Estrogen receptor (ER), Progesterone receptor (PgR),
and human epidermal growth factor receptor (HER-2). The grade of malignancy predicts
metastasis with circular logic as it is generally determined by the extent of invasion and
metastasis observed [22]. The only molecular prognostic biomarker used is hormonal receptor status. These three proteins biomarkers have been widely utilized in the clinic,
both for prognosis and for determining treatment options. Although these biomarker provide partial insight on the risk of metastasis, they are generally considered to be insufficient and might result in mistreatment. This is because about 15% of patient within the
lower risk group (i.e. ER and PgR +ve) will recur and die of metastasis and paradoxically
about 15% of patient in the high risk group (i.e. Triple negative tumor) will have a favorable outcome. No studies have demonstrated clinical utility of other molecular biomarkers
beyond the expression of these three receptors [18]. The complexity and massive molecular heterogeneity of primary and secondary Breast Cancers are major reasons for failure
to find other potential biomarkers [20, 23]. There is a hope that recent advancement in
“omics” studies would decipher the complexity of Breast Cancer and reveal genotypic and
phenotypic signatures underlying tumor heterogeneity. The promise of this approach is

4

Table 1.1: Intrinsic Subtypes of Breast Cancer.
Surrogate definitions of intrinsic subtypes of Breast Cancer according to the 2015 St.
Gallen Consensus Conference and the ESMO Clinical Practice Guidelines. Reprinted from
[24].
Intrinsic Subtype

Clinicopathologic Surrogate Definition

Luminal A

ER-positive
HER2-negative
Ki67 low
PgR hig
Low risk molecular signature (if available)

Luminal B

ER-positive
HER2-negativ
either Ki67 high or PgR low
low high-risk molecular signature (if available)

HER2 over-expression

HER2-positive
ER and PgR absent

Basal-like

Triple-negative (ductal) ER and PgR absent HER2-negative

5

that the molecular profile of each tumor can be determined and then categorized into a
larger array of subtypes, each with its own molecular biomarker, which when detected will
identify the most successful treatment regimen.

History of Metastasis
The term metastasis is originally from the Greek and means “change of place” [25].
Cancer metastasis, as a medical term, was first recorded by a famous French physician,
Recamier, in 1829 more than 150 years ago [26]. Metastasis refers to the establishment of
a secondary growth in a body organ other than the site of the primary tumor and that
is not directly connected to it [21]. Despite the clinical significance of metastasis, its genetic and biomolecular basis is not yet well understood [1]. In fact, tremendous efforts
have been undertaken in order to understand the cell biology of metastasis. One of the
earliest theories is “seed and soil” theory proposed by the British physician, Paget, in
1889. He stated, “When a plant goes to seed, its seeds are carried in all directions; but
they can only live and grow if they fall on congenial soil”. His theory simply equalizes the
contribution of primary tumor cells (he referred to them as seeds) and the potential secondary sites microenvironment (he referred to them as soil) in the establishment of the
metastatic growth [27] . This theory was dormant till 1980 when Hart and Fidler found
that intravenously injected radio-labeled melanoma cells metastasized to orthotopically
grafted lungs and ovaries but not to the grafted kidneys in a synergetic mice [28]. Their
findings demonstrate that tumor cells only colonize specific organs that have “fertile soil”
for the corresponding mature “seeds”. Subsequent to their work, a plethora of theories and
models have been proposed to explain the process of metastasis [1, 3, 14, 29, 30, 31, 32,
33, 34, 35, 36]

6

Molecular Mechanism Underlying Metastasis
Interestingly, almost all proposed models agree on the complexity of metastasis
and that it is composed of sequential steps, where each step is considered crucial to establish metastatic growth. Arrest at any step will prevent completion of the process. In
the current view, the metastatic process starts at the primary tumor site, where a genetic
alteration leads to initiation of the steps of metasatasis. Sub-populations of tumor cells
gain an invasive genotype that enables them to escape the confines of the primary tumor
and start the journey toward secondary colonization. These cells will detach from neighboring cells and invade the local stroma by secreting enzymes such as collagenase and
other proteases. Then they will penetrate the nearby lymphatic or blood vessels and intravasate. These disseminated cells must overcome the turbulence of circulation and evade
immune cells in order to survive and continue the journey to the ultimate site of metastasis. Cells that survive circulation will stop at the capillary bed of the host organ and
then extravasate. Once they are in the secondary site, they start to proliferate and establish micro-metastasis [36, 37, 30, 38, 39, 31, 40]. Although primary tumors shed million of
cells per day for every gram of primary tumor into circulation, only a very small fraction
(0.01%) of shed cells successfully establish secondary growths. Metastasis is thus a highly
inefficient process [1, 36, 31].
Despite great advancements in molecular biology and the understanding of human
genome, metastasis remains a mysterious process [41, 31]. To tackle metastasis, we need
to define target systems that are critical to steps in this process. According to postulated
model, two critical components (targets) of metastasis are unique: 1) the primary tumorderived cells that have full metastatic potential (seeds) and 2) the microenvironment of
the host organ (soil). The seeds, either circulating tumor cells (CTC) or disseminated tumor cells (DTC), have been thoroughly isolated and examined using bioinformatics approaches. However, there are no conclusive findings yet because of their unstable genetic
profile [42, 43, 44]. Recently, the host tissue microenvironment (the soil) has become a fo7

cus of attention and studies reveal that it is a more stable therapeutic target, though it is
much more poorly understood [40, 36, 45].

Is Metastasis a Late or Early Event?
Metastasis was originally believed to be a linear process. In this model, primary tumor cells undergo rounds of mutations that create genetically heterogeneous clones of cells
where some clones acquire ability to metastasize. Since a series of mutations is required,
cells randomly accrue the correct series of mutations only with time and as the primary
tumor reaches a considerable size. Scientists adopted this linear model when they noticed
a correlation between the size of the primary tumor and frequency of metastasis. Further
supporting the linear model, resecting small primary tumors was found to limit chances of
metastasis [46]. More recently, a newly proposed parallel model has gained favor over the
linear model in explaining cellular events of cancer metastasis. It is based on studies that
concluded that metastatic lesions are too big to have been initiated late in cancer progression. The parallel model states that cells start to disseminate from the primary tumor and
settle in multiple secondary organs very early in the disease progression. Only at a later
stage subsequent genetic mutations occur. Each model has strong supportive evidence, but
recent findings favor the parallel model [47, 35, 33, 36].

The Parallel (Stromal) Model of Metastasis
In 2012, Sleeman and his colleges built a more comprehensive model of metastasis
[47, 33]. This “stromal model” combines aspects of both the parallel and the linear model.
The stromal model says that there is very early crosstalk between the primary tumor and
the host organ through secreted biomolecules, which they called pre-metastatic microenvironment conditioning factors. Researchers have alluded to the hypothetical presence of
factors derived from the primary tumor for many years. Initially such tumor-derived factors were envisioned when researchers believed that cancer spread through a poisonous or
8

an infected juice that drained from the primary tumor [48]. Since we learned body circulation, the idea was abandoned with the conclusion that tumor-derived factors were instead
the common elements of body circulation (blood and lymph). Scientists turned their focus to the seed and soil as the main elements driving cancer metastasis and the idea of
circulating tumor factors promoting metastasis was forgotten. Sleeman pointed out that
such factors might enable communication between primary and secondary sites, thus accounting for issues with the parallel and linear models and helping to uncover puzzle of
metastasis at the molecular level [47, 33]. Sleemans model allows for bidirectional communication using tumor-derived factors in circulation, suggesting that there are signals from
the secondary site that are delivered back to the primary tumor via circulation, and hence
stimulate or facilitate a re-seeding process [47, 33].
With communication occurring through circulation, blood is considered as a reservoir of many biological molecules that are potentially involved in cancer growth and progression [49, 50, 51]. Analyzing cancer patients blood components (serum/ plasma) may
allow identifications of molecules that can be a signature of a particular cancer type or
cancer stage. From the standpoint of prognosis, such factors could be used to screen for
patient metastasis in a clinical setting or even be targeted to arrest microenvironment fertilization.

Premetastatic Niches
Tremendous research efforts focused on the seeds (metastatic cells in transit) and
their genotypic and phenotypic signatures. The secondary site microenvironment’s role
(the soil) in disease progression has been given less attention until recently [40, 52, 3, 53,
38, 33]. The prepared soil at a secondary site was referred to as a pre/pro metastatic niche
by Kaplan and colleagues in 2005 [54, 55]. Subsequent studies found that microenvironments at metastatic sites undergo significant molecular changes in response to factors secreted by the primary tumor and that the condition of the premetastatic niche will either
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support or suppress the growth of the DTCs [56, 57, 58, 59]. As a result, escaped DTCs
will either proliferate to establish a secondary growth, stay dormant as a micrometastasis, or die without producing metastatic disease [52, 59, 47]. The main contributors to the
formation of premetastatic niches are tumor-derived secreted factors (TDSFs) and bone
marrow derived cells (BMDCs) [60]. TDSFs recruit BMDCs from bone marrow, which
subsequently start conditioning the secondary organ to build the fertile niche [60].

Microenvironmental Responses to TDSFs
The distant site microenvironment responds to TDSFs by increasing or decreasing the expression of certain extracellular matrix proteins and recruits accessory cell types
that will help to condition the environment [30, 36, 55]. For example, matrix metalloproteinase 9 (MMP-9) is upregulated in premetastatic lungs in mice [61]. The increase in
MMP-9 expression is stimulated by activation of vascular endothelial growth factor receptor 1 (VEGFR1). Furthermore, BDMCs recruited into the lung niche were found to
be VEGFR1 positive. Surprisingly, challenging mice with tumor conditioned media (containing TDSFs) prior to tail vein injection of metastatic tumor cells resulted in formation
of the premetastatic niche in the lung. These findings support the significance of TDSFs in
conditioning the distant microenvironment and initiation of subsequent metastasis. Since
these factors are circulating in the body, they can be identified in the blood or the lymph
[62, 61, 63, 36].

Liquid Versus Tissue Biopsy
In 2012, Gerlinger and his team published a very shocking finding after they sequenced DNA from kidney tumors [64]. They found that intra-tumor heterogeneity is
significantly more extensive than previously believed. Within one single tumor, cells expressed a variety of mutations and only one third of the studied mutations were shared
across the entire mass. If this much of heterogeneity accumulates in one single mass of pri10

mary tumor, then secondary site tumors are expected to have a completely different and
highly varied mutational genotype [64]. The use of a single treatment modality that targets primary and/or secondary cells with a particular genotype would therefore miss other
cells with accumulations of different mutational signatures [64, 21, 49, 65]. For example,
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor that is used in different
chemotherapy combinations [66]. Although patients initially respond very well to Gefitinib, resistance eventually develops and the tumor evolves to be more aggressive. This
response results from new mutations occurring inside the tumor where cells continue to
accumulate mutational diversity that results in new phenotypes allowing them to survive
treatment [64].
Considering cancer as a static mutational environment is an obstacle to cancer
cure. Patients instead need to be frequently monitored for dynamic changes that emerge
as a response to treatment or other factors. Monitoring requires tissue samples, which is a
very invasive process, and since samples only represent a small portion of the tumor mass,
it can miss some mutations due to heterogeneity and its localization within the tumor.
Furthermore, the patient may have multiple site secondary growths that are inaccessible
for biopsy exacerbating this problem. Finding biomarkers in the blood that reflect the status of the tumor as it progress is a promising step towards overcoming some of the obstacles in cancer therapy. Considering the uniformity of the contents of the serum and being
a readily available specimen makes it appealing medium for clinical investigations.
In the clinic, cancer patients are exposed to different treatment regimens. Most
guidelines support the use of combination therapy such as surgery followed by adjuvant
chemo-radiotherapy [67, 68]. Chemotherapy by itself is usually composed of two or more
drug combinations. Cancer patients also often receive sequential cycles of chemotherapy
and need to be evaluated for response after almost every cycle. The current evaluation and
assessment of patients to determine the next course of treatment is either through biopsy
or radiological imaging, which lack sensitivity, are invasive, and cannot be done frequently.
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Detecting circulating biomarkers that reflect response to treatment would be a watershed
development in non-invasive treatment monitoring [69, 70, 71, 72].

Definition of Biomarker
There are several definitions for the term biomarker. World Health Organization
(WHO) and in coordination with the United Nations and the International Labor Organization, has defined a biomarker as “any substance, structure, or process that can be
measured in the body or its products and influence or predict the incidence of outcome or
disease” [73]. Biomarkers can be one of or a combination of nucleic acids (DNA, RNA or
miRNA), proteins, peptides, sugars, lipids, or whole cells (such as CTCs or DTCs) [74].
Different types of human biospecimens can be used to detect biomarkers, such as blood or
its components (plasma or serum), body secretions (sputum, urine, saliva, stool), or tissue
from organs [75].

Cancer Biomarkers
Cancer biomarkers have been studied intensively and are divided into prognostic,
predictive, and pharmacodynamic biomarkers according to their clinical uses. Prognostic biomarkers are the ones that predict the course of particular tumor. Their level can
distinguish patients with poor prognosis from those with good prognosis. The presence
or absence of prognostic biomarkers is useful to determine the treatment options for the
patient, but they do not predict response [76]. Oncotype DX, a series of Breast Cancer
gene-expression signatures, is a good example of a prognostic biomarker. It is used to predict the recurrence rate of the primary tumor after surgical removal. It also can determine
which patients will benefit from adjuvant chemotherapy after surgical resection and who
will not [77]. Another Breast Cancer prognostic biomarker is BRCA1, where high expression of BRCA1 is linked with poor prognosis in untreated patients [76].
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Predictive biomarkers are the biomarkers that predict patient response to a particular therapy. For example, Breast Cancer patient are tested for tumor hormone receptor
status because that will determine the treatment to which the patient will respond [77].
Breast Cancer primary tumors that express estrogen receptor will respond to tamoxifen,
but not necessarily to trastuzumab that will only benefit patients who are HER2 receptor
positive [76, 67].
The third biomarker category is the the pharmacodynamic biomarkers that are
mainly used in clinical trials to adjust the dose of new drugs, to measure drug activity on
biological targets, and to calculate their maximum tolerated dose. They are subsequently
used to calculate the immediate effect of a treatment on the tumor [77].

Biomarker Assay Clinical Validation
Once an empirical biomarker is identified, a clinical assay for that marker needs to
be constructed. In order to implement any biomarker assay for clinical use, it should be
tested in term of its analytic validity, clinical utility and clinical validity. First, the analytic validity is usually evaluated after the biomarker assay is commercially manufactured.
It is evaluated by the assay accuracy, reliability, and reproducibility. The clinical validity of a biomarker assay refers to the ability of the marker to further divide the group of
patients into subtype according to its level of expression. Finally, a biomarker assay will
be considered for clinical utility only if its application will results in clinical benefits more
than harm when compared to clinical practice without its use. Benefits here means a better clinical decision making than other practice or the same decision at a lower cost, less
invasive or lower risk. [18].

Genomic Versus Proteomic Biomarkers
Advancements in -omics (genomics, proteomics, lipidomics and metabolomics) allowed for high throughput studies to mine for specific cancer biomarkers circulation [78,
13

79, 80]. Each of the -omics field has advantages and limitations for biomarker development. Genomics and proteomics complement each other, though proteomics is considered theoretically superior. Although genomics provides the blueprint of life, proteins are
the ones that enact cellular functions and better reflect body physiology [81]. Although
nucleotide-based approaches can be used to assess mRNA levels in order to gauge the levels of their products, the abundance of proteins in the body often does not correlate with
corresponding mRNA levels. Therefore, protein concentration can not be determined by
studying the level of mRNA alone because the translation rate varies among different mRNAs. Beyond this, there are different isoforms of proteins generated from the same gene; it
has been estimated that almost 100,000 proteins are encoded by only 20,235 genes in human [82]. Furthermore, translated proteins undergo post-translational modifications that
creates further complexities to the protein structure that do not exist at the mRNA level.
Post translational modifications, such as phosphorylation, acetylation and glycosylation,
result in different copies of the same protein having its own physiological function. Therefore, in order to study a rapidly changing physiology, we need to examine proteins directly
in laboratory experiments [81, 83, 80].
The study of proteins is complicated by the complex network of interaction between
them. Scientists were surprised with the complexity of protein interactions found in yeast
Saccharomyces cerevisiae, despite it being a simple model organism. One study revealed
the presence of a single large network of 2,358 interactions between 1,548 proteins [84].
The human protein interaction network cannot be uncovered by genomic studies [81, 85].
Therefore, proteomic studies provide a wider understanding of molecular pathways and
interactions in physiological systems than genomics. Fortunately, proteomic studies are
increasingly prevalent due to rapid advancement in high throughput technology and in
response to the sore need for disease specific biomarkers [86].
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Clinical Proteomics in Biomarker Discovery
The goal of clinical proteomics is to characterize protein pathways, interactions,
localization, and signaling events that are relevant in disease. It have been applied extensively in BC research and provide a treasure of information that explain or partially define
cellular pathways. Recently BC metastasis has gained a focused attention and efforts were
directed towards completing the molecular picture of metastatic process. Here, we focus on
the proteomic analysis of Breast Cancer progression and discuss some of the key issues.

Techniques of Proteomics
Proteomic studies are divided into many categories such as expression, functional,
modification, localization and protein-protein interaction depending on the aim of the
study. They complement each other to provide the complete picture of a particular protein or a cellular pathway. Here, we focus on the expression proteomics that aims to quantify the protein content in the biospecimens that represent BC metastasis. Expression proteomics studies encompasses different techniques with distinct advantages and limitations.
The choice of the proteomic techniques depends on the biological system under study and
the aim of the study (quantitative or qualitative). In fact, some proteomic techniques can
only be applied in specific biological samples but not in others. For example SILAC needs
a prior culture of the studied protein with isotopically labeled amino acids which makes it
impractical in human bio-fluid [87].
In general, proteomic analyses are divided into Mass Spectroscopy (MS)-based and
non-MS based techniques [88]. The non-MS proteomic approaches—also called targeted
proteomics— use specific antibodies or other ligands against a particular, and known, protein, requiring prior knowledge of the protein under study. This can be done by enzymelinked immuno sorbent assay (ELISA), immunohistochemistry (IHC), Western blotting,
tissue microarray (TMA) and Protein microarray (PMA) [89]. On the other hand, in MS
based proteomics there is no need for foreknowledge of proteins under study. It is more
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informative as it might reveal previously unstudied proteins and even show unexpected
interactions despite being technically challenging [90].
Previously, proteomic studies were only capable of analyzing few samples and therefore could not provide an accurate protein quantification. The recent advancement in mass
spectroscopy (MS) based proteomics greatly improved protein quantitation even in complex samples such as human specimens. The innovations in sample preparation, separation, and computational proteomics together with the implementation of hybrid mass
spectrometers that combine high resolution, high mass accuracy and wide dynamic range
all enable more confident protein identification and quantification at a large scale. As a result, the MS-based proteome analysis has grown exponentially in the last decade yielding
plethora of identified proteins (biomarkers) that represent different diseases [86].

Quantitative Analysis by Mass Spectroscopy
Mass spectroscopy based proteomics are capable of providing absolute and relative quantitation of proteins in samples under study. The quantitative MS approaches are
either labeled or label free (Table 1.2). The label free quantitation methods includes the
spectral counting approach and the Peptide peak intensity approach. In spectral counting,
proteins are quanrified according to the number and abundance of MS/MS spectra that is
produced by the fragmentation. This is based on the concept that highly abundant protein
will provide more spectra with higher intensities than less abundant proteins. Comparing the number and intensity of the MS/MS spectra of a particular protein between samples will provide relative quantitation. Peptide peak intensity measurements could provide
quantitation of the protein under study through the extraction of the chromatographic
peak of the corresponding peptide in the ion chromatograms from a capilary Liquid Chromatography Mass Spectrum (cLC-MS). Comparing the peak areas of the same ion/peptide
between different runs and samples will provide a relative quantitation. The labeled quantitation methods include the use of multiple labeling methods such as metabolic labeling
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(e.g SILAC), isotopic labeling (e.g.ICAT) and isobaric labeling(e.g. iTRAQ). They provide
relative or absolute quantitation and vary in their proteomic coverage as described in table
1.2.

Bottom Up vs Top Down Proteomics
There are two types of MS-based proteomics, referred to as bottom up and top
down approaches. In the bottom up, or shotgun approach, a protein is identified through
detection of peptides that result from the proteolytic breakdown of that particular protein
[91, 92, 93]. In a typical bottom up proteomic experiment, specimens containing intact
proteins are treated with a proteolytic enzyme to break them into their corresponding peptides and then loaded into cLC-MS/MS. The proteins are later identified by comparing the
fragmentation pattern of the daughter peptides with a protein database. This approach
does not identify post-translational modifications and is complicated when a single peptide is shared by more than one parent protein [82, 94]. These limitations are overcome
by top down proteomics, where intact proteins are analyzed. Therefore, top-down has the
advantage of being able to detect post translational modification and distinguish between
protein isoforms. A further advantage over the bottom up approach is its ability to characterize small low molecular weight (LMW) proteins [95, 96, 94, 97]. The major challenge
in the top down approach is the wide dynamic range of protein abundance in human samples. This has been overcome by the implementation of multiple separation steps prior to
introducing the samples into the instrument [95, 96], as well as by enrichment of LMW
during precipitation of high abundance proteins [97, 96, 94, 98].

Mass Spectrometry-Based Biomarker Discovery Workflow
With advances in proteomics techniques, it is becoming more feasible to study hundreds or even thousands of proteins in a single experiment [85, 99]. High throughput proteomic studies usually involve mass spectrometry (MS) or microarray technology [86]. The
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Table 1.2: Summery of the Quantitative MS Approaches.
Reprinted with permission from [100].
Quantitation
method
Labeled
SILAC
ICAT
ITRAQ

Dynamic range

12
12
2

Number
of
samples

Proteomic
Coverage

2 to 3
2
2 to 8

Medium
Poor
Medium

Relative

many

Medium

Relative
Relative

many
many

Good
Good

Quantitation
Nature

Relative
Relative
Relative/Absolute

Label-free
2D gels
Ion intensities
Spectrum count

1 to 4 (stain
dependent)
3
3
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general workflow of a global mass spectrometry-based biomarker discovery experiment occurs in 4 steps [86]. The first step is choosing the most appropriate disease-related samples, which are then processed to deplete the high abundance large MW proteins. Next,
processed samples undergo a pre-fractionation step, using either gel electrophoresis or
chromatography. At this stage, samples are then loaded into the MS instrument and the
levels of individual proteins are quantitatively assessed for comparison between sample
groups. The last step is validation of identified proteins or protein panels using independent analytical approaches.

Low Molecular Weight Peptides as Disease Signature
Recently, proteomic studies have been directed toward the low abundance and low
molecular weight (LMW) proteins that are less than 30KDa [98]. It has been found that
disease specific molecular signatures, including central regulators of biological pathways,
are usually of low MW and present at low concentration [101]. Furthermore, It has been
estimated that almost 50% of the human peptidome is composed of peptides that are less
than 26.5 kDa [102]. Low MW proteins are categorized into cytokines, peptide hormones,
small signaling proteins, or fragments of a larger cellular proteins. Previously, these low
MW proteins were considered as cellular trash, though they are now known to have physiological significance [103, 81, 104]. Low MW proteins were hard to detect in gel-based
proteomic studies because they stain very poorly and they migrate rapidly during electrophoresis [102].
The potential diagnostic significance of these molecules was revealed when the serum
proteome of ovarian cancer was examined using MALDI-MS and significant biomarkers
were detected in the Low MW range [105, 106]. Discovering the low MW range of human
proteome is ongoing, but is incomplete and no examples of low MW biomarkers have yet
reached diagnostic utility in clinical settings.
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Challenges in Serum Proteomics
Proteomics can be applied to any biological samples: cell lines, clinical tissue samples and biofluids such as serum, tears, urine and organ aspirates. The complexity of the
human proteome depends on the samples used for the study. Body fluids, such as blood,
urine and saliva, are the most complicated and challenging samples for proteomic study,
but are also the most clinically relevant [86]. Human serum/plasma is considered the most
accessible body sample for clinical biomarker investigation; and therefore it is appealing
clinically as a minimally invasive source for diagnosis and screening. It contains a vast
number of molecules that are shed out from almost every tissue of the body, all of which
vary in their molecular weight. This makes the serum a vast and diverse reservoir of signals that reflect body physiology [107, 108].
Despite being readily accessible, human serum proteomics is technically challenging. The biggest challenge is the wide dynamic range of proteins in human serum, which
reaches a magnitude as high as 12 units. This is because more than 90% of serum proteins are of large molecular weight and these mask the visualization of more divers low
MW proteins that are believed to be disease specific. These low MW serum proteins are
called the “hidden proteome” for this reason. The hidden proteome is mainly composed
of proteins of less than 50 kDa, which are either small circulating proteins or fragments of
cellular proteins that have diffused into circulation. Low MW protein fragments in serum
have their own physiologic function and the diagnostic impact can be very different than
the parent protein. Data contradict the original belief that circulating protein fragments
represent the level and function of their parent [104]. For example, low MW hyaluronan
(LMW-HA) levels in serum, but not the parent HA levels, were found to correlate with
Breast Cancer metastasis. Although total HA levels are elevated in primary Breast Cancer, it has no role in Breast Cancer progression. [109].
In order to uncover these low MW proteins in serum, we need either to carefully
separate them from the large MW or to deplete the large MW from the sample before
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conducting proteomic study. Large MW protein in human samples suppress the low MW
protein signals in the MS and makes them difficult to quantitate [110, 111, 112, 113, 114].
Several separation methods, such as gel electrophoresis [115, 116, 117], immunodepletion
[118, 117], and chromatography [119, 117] have been implemented and all give a better
sensitivity in mass spectrometry analysis. Furthermore, the use of enrichment strategies
have been shown to be effective in depleting the large MW serum proteins. Enrichment
strategies could be through organic solvents precipitation, ultrafiltration, solid phase extraction and others [120, 121, 122, 123, 124, 125, 126, 120, 110, 127, 111, 128]. Acetonitrile
precipitation is considered superior to other enrichment approaches [122, 128, 127, 110].

Acetonitrile Precipitation
Acetonitrile is an organic solvent that has been used to precipitate high abundance,
large MW proteins. It has been found that it also dissociate the low MW protein from
their carrier proteins making them available for proteomic study [110]. When cLC-MS
chromatogram of acetonitrile treated serum sample compared with untreated serum sample cLC-MS chromatogram, the total-ion chromatogram (TIC) of the treated sample had
more numbers of molecular species than the untreated samples [128]. This reflect the power
of acetonitrile precipitation in enriching the low MW proteins pool for further proteomic
study.
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CHAPTER 2: Literature Review

Biomarkers for BC Progression
The application of the high throughput screening techniques in BC cancer research
provided several putative biomarkers that needs further evaluation for their analytical validity, clinical validity and clinical utility. Table 2.1 summarizes the most recent potential
proteomic biomarkers that have been identified and found to play a role at one or more
stages of BC progression and invasiveness. The list is providing examples of the most recent identified proteins and it is not an exhaustive list.
Metaphorically speaking, “the water is everywhere, but little is yet ready to drink”,
describes the current state of the amount of identified proteins that are associated with
BC progression but are not yet ready for clinical utility. Despite the long list of empirical proteins that claims success, FDA has not yet approved the use of any MS-based protein biomarker in the clinic [86, 18]. It is worth mentioning here that there are some BC
metastasis empirical biomarkers are in their way toward the clinic. For example, there
are accumulating evidences toward the use of Ki67 as a prognostic indicator for the progression of BC but not as a predictor of treatment benefit as indicated in Table 1.1 [129].
Additionally, urokinase-plasminogen activator (uPA) and plasminogen activator inhibitor
(PAI-1) have been recently recommended by the ASCO for the determination of prognosis in lymph node negative Breast Cancer [130]. The proposed biomarkers are promising
and even if they are not sensitive to predict outcome, they might add an important piece
of information towards the understanding of BC metastasis.

22

Table 2.1: List of Most Recent Protoemics Studies on Breast Cancer Progression.
Experimental methodology

Proteomic technique

Findings

Reference

Breast cancer tissues

LC-MS/MS

Significant up-regulation of PDI A3 was detected only in
the metastasized breast cancer

[135]

Breast cancer cell lines

Nano-UPLC-MS-MS

EDIL3 on exosomes promotes breast cancer invasion via
integrin-FAK signaling

[136]

Breast cancer cell lines

iTRAQ-nano-HPLCMS/MS, IHC in tissue

RAB1B is significantly down-regulated in highly
metastatic breast cancer cells

[137]

Breast cancer cell lines

2DE-MALDI-TOF/TOF,
Wastern blot

Downregulation of RhoGDI in MCF7 and MDA-MB-231
cells increased the invasion and migration of BC cells

[138]

Breast cancer cell lines, animal
study

2DE-MALDI-TOF/TOF
Wastern blot

STC1 is positively associated with the development, progression and metastasis of BC especifically to the lung

[139]

Breast cancer cell lines, animal
study

nano LC-MS/MS

High expression of LTBP3 and SNED1 correlates with
poor outcome for ER(-)/PR(-)breast cancer patients

[140]

Breast cancer cell lines and
animal study

SILAC-LC-MS/MS, IHC

[141]

Breast cancer cell lines and
animal study

LC-MS/MS , IHC

LRRC59 positively correlate with BC aggressiveness and
metastasis, CD59 and CSPG4 inversely correlate with
metastasis
hnRNPM is associated with aggressive BC [142]

Breast cancer cell lines and
tissues

SILAC-LC-MS-MS, IHC

Reduction of lung metastasis when CYB5R3 expression
was significantly reduced

[143]
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Experimental methodology

Proteomic technique

Findings

Reference

Breast cancer cell lines and
tissues

HPLC- LTQ-Orbitrap

High levels of IDH2 and CRABP2 and low levels of
SEC14L2 are prognostic markers for overall breast cancer survival

[144]

Breast cancer cell lines and
tissue

Discovery: 2D-DIGELC/MS/MS, validation:
IHC

composite biomarker comprising CAPG and GIPC1 was
associated with development of bone metastasis and reduced survival

[132]

Breast cancer serum samples

Recombinant antibody
microarray platform

21-candidate protein biomarker signature associated with
metastasis, included cytokines (IL-6, IL-18) involved with
cell migration, infiltration and angiogenesis

[145]

Breast cancer serum samples

Chemiluminescent assay,
IHC

High serum HER-2 extracellular domain (ECD) levels
associated with a worse disease-free survival and overall
survival in primary operable BC patients

[146]

Breast cancer serum samples

SELDI-TOF-MS,
Wastern blot

High expression levels of SAA in sera of almost all
advanced-stage cancer patients

[147]

Breast cancer serum samples

Luminex liquid protein
chip

Decreased expression of CP-1 and IP- 10 significantly
correlated with patients who had more positive lymph
nodes

[148]

Breast cancer serum samples

ELISA

Serum amyloid A (SAA) protein indicated presence of
lymph node metastases and distant metastases

[149]

Breast cancer serum samples

ELISA

Serum cadherin-5 discriminated patients with recurrent
BC from those with no sign of recurrence (90% specificity)

[150]
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Experimental methodology

Proteomic technique

Findings

Reference

Breast cancer serum samples
and cell lines

HPLC followed by
UV/refractive index dual
detection

Elevated serum levels of LMW-HA, but not total HA,
correlate with BC metastasis

[109]

Breast cancer serum samples
and cell lines

ELISA

Higher serum CIP2A levels positively associated with the
aggressive BC in vivo and ivitro

[151]

Breast cancer tissues

iTRAQ-2DLC-MS/MS,
IHC

CPB1, PDLIM2, RNF25, RELA, STMN1, TMSB10,
TRAF3IP2, and YWHAH as proteins correlating with
lymph node positivity of low grade breast cancer

[152]

Breast cancer tissues

HPLC- ESI-LTQOrbitrap screen, IHC
validation

ATPIF1, CK17, thrombomodulin and tubulin -chain are
part pathways involved in cell adhesion, migration pathways and immune response

[153]

Breast cancer tissues

2DE-MALDITOF/TOF/MS/MS

1433G, 1433T, K1C19, K2C8, PSME2, SNAA, TPM4,
TRFE and VIME were up-regulated in PBT while
ALDH2, GDIR2 and K1C19 were up-regulated in LNM

[154]

Breast cancer tissues

iTRAQ sets for LCMS/MS , SRM, IHC

High expression of DCN was associated with higher risk
for lymph node metastasis, high expression of HSP90B1
was correlated with higher risk of developing distant
metastasis

[155]

Breast cancer tissues

2DGE- MALDI-TOF,
wastern blot

Deregulation of multiple S100 protein members is associated with breast cancer progression

[155]

Breast cancer tissues

2D-PAGE-LC-MS/MS

Higher expression of Stat1 and the HLA II gamma subunit CD74in LN +ve tumor

[135]
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Experimental methodology

Proteomic technique

Findings

Reference

Breast cancer tissues

nLC-MS/MS

10 proteins were downreg- ulated (CMPK1, AIFM1,
FTH1, EML4, GANAB, CTNNA1, AP1G1, STX12,
AP1M1, and CAPZB), whereas one protein was upregulated (MTHFD1) in TNBC

[156]

Breast cancer tissues

IHC

Significant correlation between the cytoplasmic expression
of VCP and adverse prognosis in breast carcinoma

[157]

Breast cancer tissues

IHC

C6orf106 promote tumor progression in the invasive
breast cancer

[158]

Breast cancer tissues

IHC

Data support a role of SIRT1 protein as tumor suppressor
in luminal A breast cancer

[159]

Breast cancer tissues

IHC

Overexpression of G6PD protein predicted a high risk of
recurrent metastasis and poor PFS during follow-up

[160]

Breast cancer tissues

Western blotting, IHC

Down-regulated CDK10 expression frequently occurs in
BC and correlates with disease progression and poor survival

[161]

Breast cancer tissues

TMA

CCR7 and CXCR4 were expressed more often in BC bone
metastases than in visceral metastases

[131]
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Organ Specific Distant Metastasis
Biomarker Associated with Bone Metastasis
We notice from the above list in table 2.1 that in general, couple of studies were focusing in organ specific BC metastasis while others were mining for protein that associate
with BC progression and invasiveness in general. Liu found that the expression of CCR7
and CXCR4 combinedly is more predictive of bone metastasis than their sole expression
[131]. Another composite biomarker comprising of CAPG and GIPC1 has been implicated
to the development of BC induced bone metastasis as well [132]. Bone is a common destination for BC tumor. It has been estimated that up to 75% of patients with metastatic
BC will have a bone metastasis [133]. Bone metastasis is considered a sign of poor prognosis because of the severe skeletal complication that impact patients life [134]. Developing a
signature biomarker to predict the risk of developing bone metastasis will help to improve
BC patient management and prognosis.

Biomarker Associated with Lung Metastasis
The second common destination for BC metastasis is the lung. Approximately
60% of Breast Cancer patients have secondary growth in the lung. In fact, about 21% of
BC patient have lung metastasis as the sole secondary growth. Several biomarkers have
been proposed to associate with lung metastasis in BC. For example, CYB5R3, LDHA,
NPC1, NRH2 protein expression has been linked to lung metastasis. Moreover, inhibition
of CYB5R3 was highly associated with reduction in lung metastasis [143]. In addition,
Olkhanud suggested that CCR4 is a metastasis-associated receptor that when targeted,
it decreases lung metastasis [162]. Furthermore, STC1 as a single biomarker found to positively associate with BC metastasis to the lung. [131]. The role of MMP9 on metastasis
was examined using an animal study. It showed that suppression of MMP9 markedly reduced lung metastasis [61].
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There are other proteins that are associated with BC aggressiveness and metastasis in general with no organ preference. For example serum amyloid A (SAA) protein was
highly expressed in sera of BC metastatic patients with a metastasis in multiple distant
sites [149]. Interestingly, Carlsson conducted a longitudinal study where he screened BC
sera at different intervals of the disease for a period of 3 years to identify proteins that can
predict recurrence. He built a serum protein signature, which contain couple of cytokines
and are involved in cell migration, infiltration and angiogenesis [145]. It is very important
to stress that previously mentioned protein biomarkers are not an exclusive list but rather
reflects the most recent published studies in literature.

Multiple Markers Reflect Complicated Pathway
The striking observation here is that vast number of proteins have been identified
to be associated with BC progression. This might reflect the complex pathway and protein interaction involved in this process. Therefore, all the identified markers could add
a new understanding to the mechanism of metastasis and if they are not good biomarkers per se, they could direct further research to reach a better biomarker model. In addition, the study findings are highly dependent on the used specimen and the proteomic
techniques utilized. An ample number of cell types, BC tissues, and biological fluids have
been studied in an effort to identify biomarkers that can cross their way to the clinic. The
specimen used in proteomic studies has a critical role in determining the clinical relevance
of the detected protein. As a matter of fact, the proteomic profile complexity is increasing
as we move from cell lines study, animal studies, tissue biopsy to blood and biofluid. Although human blood and biofluid are the most challenging and their proteomic profile is
very complicated, they are providing the most clinically relevant findings [86].
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Conclusion
The use of biomarkers could only replace other practiced diagnostic and prognostic
guidelines if they only provide better insight towards the disease progression or the similar
insight at a lower cost and less invasiveness. BC metastasis biomarker studies will be easier if a comprehensive understanding of the metastatic process exists. Since Breast Cancer
is very dynamic and heterogeneous, there are always emerging new molecular mechanism
and pathway. Therefore any identified potential marker will need continuous re-evaluation
to get the best practice [163].

29

CHAPTER 3: Methods

Study Population
Proteomic studies can be applied in any biological specimen. The most commonly
used samples for cancer research are cell lines, tissue biopsies, animal model and biofluids.
The study of any of these samples can uncover a molecular aspect related to cancer initiation, cancer progression or response to therapy which can be considered as biomarkers
for clinical use. Technically, biomarkers that are identified and validated in a less invasive
samples are more enviable [164]. Serum/plasma are the least invasive and readily available
samples and therefore considered as optimum biospecimens for biomarker discovery (see
Table 3.1). In our project, we used commercial serum samples that represent metastatic
and non-metastatic stages of BC for both the initial and confirmatory studies. Table 3.2
is showing the clinical stages of Breast Cancer and at which stages it is considered metastasized. For our study samples, we considered all patients classified in stages 0, I, IIa with
no local (lymph node) or distant organ metastasis as Non-metastatic, and all patients in
other stages as metastatic.

Experimental Pipeline
This study was conducted through 3 phases, the discovery phase, training phase
and testing phase. The biomarkes that have been discovered in the serum samples in the
initial discovery study were tested for persistent significance in independent serum samples
set in the training set. A confirmatory testing set were then conducted using a new serum
sample to further confirm and validate the findings. We aimed to get more confidence that
the peaks identified are truly associated with the experimental condition, rather than a
statistical expectation from having a lot of peaks to examine.
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Table 3.1: Summery of Sources of Biomarkers for Discovery Platforms. Reprinted with
permission from [86].
Sample

Advantage

Disadvantage

In vitro cell culture

Easy to obtain; no ethics;
abundant sample quantity; good for characterizing cell-specific responses

Lack of heterogeneity; may
not represent clinically relevant results

Tissue biopsy/core sample

Accessibility to samples
stored, long term; direct
comparison to standard
diagnosis; tissue-level representative profiling

Potential for sample degradation; require large validation datasets; invasive
sample collection

Urine/blood

Easy to obtain; express
representative protein and
gene expression of a large
number of cell types

Low marker concentration;
high sample complexity;
technically difficult to detect
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Table 3.2: Clinical staging of Breast Cancer.
Reprinted with permission from American Joint Committee on Cancer 7th edition, BC
staging.
N1: Metastasis to movable ipsilateral level I, II axillary lymph nodes.
N2: Metastases in ipsilateral level I, II axillary lymph nodes that are fixed or matted.
N3: Metastases in ipsilateral infraclavicular (level III axillary) lymph nodes.
Stage

Primary tumor

Lymph node

Distant metastasis

Survival rate

0

≤2 cm

None

None

100%

I

≤2 cm

None

None

98%

IIa

≤2 cm

N1

None

88%

IIb

>2 cm,≤5 cm

N1

None

88%

IIa

>2 cm,≤5 cm

N2

None

52%

IIb

>5 cm

N2

None

52%

IIc

Any size

N3

None

52%

IV

Any size

Any involvement

Detectable

16%
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Initial Study
For the initial study, six samples of each stage (stage I and stage III) were purchased from Proteogenex. We used the following criteria to match these patients as closely
as possible between the two groups: race, age and absence of comorbid diseases and tumor
subtype. The provided serum samples lacked vital information such as time of sample collection (whether pre or post cancer therapy). Table 3.3 shows demographic, clinical history
and diagnosis of patients in the the initial study.

Confirmatory Study
For the confirmatory study, we purchased serum samples from Conversent Bio. It
included 19 samples in stage I and 20 samples in stage III. A variety of sample types were
included, as we aimed to detect biomarkers of metastasis in a way that is not dependent
on factors such as treatment regimens, race or age. Table 3.4 demonstrate the demographics, diagnosis and treatment of the patients used in the confirmatory study. All samples
in both studies were coded without personal information. According to our conversations
with both companies, samples in both studies were exposed to the same environment from
collection to storage with no prior thaw and freeze cycle. Specimens were maintained at
-80 C during pre-processing and post-processing.

Samples Preparation
Despite the high clinical prevalence of serum/plasma proteomics and its easy accessibility, it is technically challenging. The challenges in serum proteome is due to the wide
dynamic range (upto 12 orders of magnitude) of its protein content [165] which can not
be covered by the current available proteomic approaches that are limited to linearity of
just over 3 orders of magnitude [166]. It has been very confronting to uncover this hidden
serum proteome because of the masking effect of the high abundance low MW which constitute more than 90% of serum proteome [104]. Identification of these cancer-causing pro33

Table 3.3: Demographics of the Initial Study Samples.
IDC: Infiltrating ductal carcinoma, ILC: Infiltrating lobular carcinoma.

I

Histological
Diagnosis
IDC

I

IDC

63

Caucasian

No

I

IDC

67

caucasian

No

No
Ischemia;
hypertension
Ischemia

I

IDC

46

Caucasian

No

No

I

ILC

46

Caucasian

No

Chronic cholecystitis

IIA

IDC

51

Caucasian

No

No

IIIA

IDC

46

Caucasian

No

No

IIIA

IDC

51

Caucasian

No

No

IIIA

IDC

55

Caucasian

No

IIIA

IDC

39

Caucasian

IIIC

IDC

60

Caucasian

No
Uterus Cancer
(Grandmother)
No

Chronic Cholecystitis

IIIC

ILC

45

Caucasian

No

No

Stage

Age

Ethnicity

63

Caucasian

Family
History
No

34

Personal History

No

Table 3.4: Demographics of the Confirmatory Study Samples.
IDC: Infiltrating ductal carcinoma; ILC: Infiltrating lobular carcinoma; Tx:
Treatement history, TAC: Taxotere+Adriamycin+Cyclophosphamide, AC: Adriamycin+Cyclophosphamide.
Histological
Stage

Treatment Status

Age

Race

Ethnicity

Diagnosis
I

IDC

Taxol

54

Black

Non-Hispanic

I

IDC

Taxol

77

White

Non-Hispanic

I

IDC

53

White

Non-Hispanic

Taxotere; Herceptin;
Carboplatin
I

Undefined

TAC

56

White

Non-Hispanic

I

IDC

Reclast

70

White

Non-Hispanic

I

IDC

Post Tx

80

Black

Non-Hispanic

I

Undefined

Post Tx

56

White

Non-Hispanic

I

IDC

Active Hormone Tx

85

White

Non-Hispanic

I

IDC

Active Hormone Tx

65

White

Non-Hispanic

I

ILC

Active Hormone Tx

66

White

Non-Hispanic

I

Undefined

Active Hormone Tx

42

White

Non-Hispanic

I

IDC

Active Hormone Tx

64

White

Non-Hispanic

I

Undefined

Active Hormone Tx

75

White

Non-Hispanic

I

IDC

Active Hormone Tx

53

Black

Non-Hispanic

I

IDC

Active Hormone Tx

72

White

Non-Hispanic

I

IDC

Active Hormone Tx

59

White

Non-Hispanic

I

Undefined

Active Hormone Tx

60

White

Non-Hispanic

I-A

IDC

Taxotere; Cytoxan

55

Black

Non-Hispanic

I-A

IDC

Cytoxan; Taxotere

71

White

Non-Hispanic

35

I-A

IDC

AC; Taxotere

73

White

Non-Hispanic

III

IDC

Active Hormone Tx

36

White

Non-Hispanic

III

IDC

65

White

Non-Hispanic

69

White

Non-Hispanic

49

Black

Non-Hispanic

54

White

Non-Hispanic

75

White

Non-Hispanic

65

White

Non-Hispanic

63

White

Non-Hispanic

Adriamycin; Cytoxan;
Taxotere
III

IDC

III

IDC

Taxotere; Cytoxan
Adrimyacin;
Cytotoxan; Taxotere

III

IDC

III

IDC

Carboplatin/Taxol
Taxol; Adriamycin;
Cytoxan

III

IDC

III

ILC

Taxotere
Doxorubicin;
Cyclophosphamide

III

IDC

Active Herceptin

56

White

Non-Hispanic

III

Undefined

Active Hormone Tx

47

Black

Non-Hispanic

III-A

IDC

Active Hormone Tx

55

Black

Non-Hispanic

III-A

IDC

Active Hormone Tx

53

White

Non-Hispanic

III-A

IDC

Unknown

30

Black

Non-Hispanic

III-A

IDC

Unknown

60

White

Non-Hispanic

III-A

Undefined

Active Hormone Tx

56

White

Non-Hispanic

III-A

ILC

Unknown

71

White

Non-Hispanic

III-A

Undefined

Active Hormone Tx

82

White

Non-Hispanic

III-A

IDC

Herceptin; Tamoxifen

48

Black

Non-Hispanic

III-C

IDC

Unknown

75

White

Non-Hispanic
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tein biomarkers in the human serum proteome is like “looking for a needle in a haystack”.
One of the strategies designed to overcome the issue of dynamic range involved the use of
protein pre-fractionation coupled with depletion methods to remove abundant proteins in
the plasma proteomes. Different methods have been used for sample pre-fractionation and
biomolecule separation such as immobilized dyes (cibacron blue), immunoaffinity-based
techniques, solid phase fractionation, liquid chromatography, or low-molecular weight fraction enrichment [167, 168, 169, 170, 171, 172, 165]. In our study, we applied a unique proteomic approach that composed of a simple depletion method by acetonitrile (ACN) coupled with a liquid chromatography separation interfaced with Quadropole Time of Flight
Mass Spectroscopy (Q-TOF/MS).

ACN Precipitation
We washed out the high-abundance proteins (those with MW less than 20 kDa) by
adding acetonitrile in a ratio to serum of 2:1; following an established acetonitrile precipitation protocol [173, 127, 122]. Although acetonitrile precipitation sacrifices most proteins,
it does dissociate the small unobservable peptides from their carriers making them available for MS analysis [110, 111]. A BCA Protein Assay (Pierce Microplate BCA Protein
Assay Kit; Thermo Scientific) was used to determine the apparent protein concentration of
ACN treated samples. An aliquot containing 4 µg protein was lyophilized to 10 µL (CentriVap Concentrator Labconco Corporation, MO, USA) and then acidified by adding equal
volume (10 µL) of 88% Formic acid. The samples then were loaded into capillary liquid
chromatography mass spectroscopy ( cLC-MS).

Liquid Chromatography Mass Spectroscopy
Several proteomic approches have been applied for biomarkers dicovery including
two-dimensional (2D) gel-electrophoresis, liquid chromatography coupled with mass spectrometry (cLC-MS), and protein- and antibody-based microarray. In fact, cLC-MS based
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proteomic technologies is considered the method of choice for proteomic profiling of human complex biospecimens [174] because of its highly sensitive analytical capabilities and
a relatively large dynamic range of detection. The Chromatographic Reversed-phase capillary liquid chromatography (cLC) was operated with an LC Packings Ultimate Capillary
(HPLC) pump system, with a Famos autosampler (Dionex, Sunnyvale, CA, USA). The
cLC system composed of a 1 mm (16.2 µL) dry packed MicroBore guard column (IDEX
Health and Science, Oak Harbor, WA, USA), coupled to a 15 cm×250 µm i.d. capillary
column, slurry-packed in-house with Poros R1 reversed-phase medium (Applied Biosystems, Foster City, CA, USA). To generate a gradient mobile phase, we used 98% HPLCgrade water, 2% acetonitrile, 0.1% formic acid as an aqueous phase and 98% acetonitrile,
2% HPLC-grade water, 0.1% formic acid as an organic phase. The gradient was set as follows: 3 min of 95% aqueous and 5% organic phase, followed by a linear increase in organic
phase to 60% over the next 24 minutes. The gradient was then increased linearly to 95%
organic phase–5% aqueous phase over the next 7 minutes, held at 95% organic phase for 7
minutes and returned to 95% aqueous phase.
The cLC system was interfaced to Agilent 6530 Accurate-Mass Q-TOF LC/MS
system. The ESI source was operated in positive ion mode. The scans were collected at
8 spectra/s and the mass spectra were within the range of m/z 500 to m/z 2500. The samples were run in sets that are randomly assigned with an approximately equal number of
stage I and stage III samples. The same instrument was used for tandem MS in order to
identify the promising markers where we used targeted MS/MS, and scans were collected
at 1 spectra/s. Agilent MassHunter Qualitative Analysis B.06.00 software was used to extract the data and ion intensities.

MS Data Analysis and Time Normalization
In any proteomic study there are several biological and non-biological variations in
mass spectra that are not reflective of disease status. One way to minimize elution time
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variability between samples is through normalizing time markers and peak alignments
[122, 173, 127]. The time-marker normalization concept assumes the existence of ten endogenous species that elute every 2-3 minutes in the cLC chromatogram of human sera.
The compounds in the series elute at approximately two-minute intervals from each other.
This allowed for the same time windows to be considered for each specimen run. Data
were organized in two-minute windows centroided on each marker or where there were
gaps between two time markers. The time markers allowed for time normalization, providing uniformity in chromatographic elution windows over the important chromatographic
region (˜15 to ˜35 minutes) as described in detail in [128]. We applied the time-marker
normalization to our data and created 10 2-minute time windows for each sample. The
m/z of the ten time markers were: 733.3 (z = +2), 721.3 (z = +2), 1006.0 (z = +2), 1013
(z = +5), 547.3 (monoisotopic) (z = +1), 547.3 (z = +1), 1047.7 (z = +1), 637.3 (z =
+1), 781.5 (z = +1), and 1620.2 (z = +1), details are in Table 3.5. Then, the samples’
mass spectra were overlaid after we color-coded them. Interesting peaks were picked upon
visual assessment of the difference in their heights between stage I and stage III samples
(Figure 3.1). Then peak heights were extracted from the ion count using the instrument
software.

Data Normalization and Initial Marker Filtering
Peaks that appeared quantitatively different between stage I and stage III were
considered for further analysis. We extracted their ion counts in every sample and recorded
the peak height that corresponds to the marker intensity in each sample. To minimize
non-biological variation that may arise from different runs on the instrument, we normalized the extracted intensities by calculating the ratio of each intensity value to the mean
across all samples for the same marker. Normalized intensities were evaluated statistically
using Students t-test. All markers with a p-value less than 0.05 in the initial study were
evaluated for their predictive power in the confirmatory study. We assumed that some
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(a)

(b)

Figure 3.1: Visual Assessment of the Mass Spectra.
Different colors indicate sample stage (blue for I and red for III). (a) m/z 819.43 is a potential marker; (b) m/z 439.25 shows no visually significant difference.
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Table 3.5: Details of the 10 time markers.
Reprinted with permission from [128].
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markers might have modest predictive power in isolation but that this predictive power
would increase when combined with other markers in our subsequent machine learning
analysis.

Evaluation of Potential Batch Effect
It is almost inevitable in a high throughput study to introduce batch effect due to
the splitting of samples into batches that are run under different conditions [175]. This
may lead to biases that confound with the original study design [176]. We used two approaches to minimize such biases: 1) we analyzed data from the initial study (first 12 samples) separately from the data from the confirmatory study, and 2) we applied the ComBat
algorithm [177] to data from the confirmatory study, which had been loaded into the MS
on sequential days due to the long run time in the mass spectroscopy (one hour run per
sample followed by 45 minutes wash).

Confirmatory Study Workflow
An arbiter who was not part of the analysis team blinded the 39 samples from the
confirmatory study by assigning generic labels to each sample. These labels did not indicate whether the samples were stage I or stage III samples. The samples were processed on
cLC-MS in batches that included an approximately equal number of stage I and stage III
samples, according to the order created by the arbiter. Candidate markers intensities were
extracted, normalized by the mean marker value and then evaluated by the analysis team.
At this stage, the 39 samples were randomly divided into training (n = 24) and testing (n
= 15) sets, each with an approximately equal number of stage I and III samples. At this
point in time, the analysis team was made aware of the stage status of the training samples but not of the testing samples.

42

Multi-marker Model
The previously believed concept that the risk of metastasis can be determined by
the presence or absence of one particular molecular marker is far from reality [178]. The
very complicated interaction between several different molecules within a single pathway
and the overlap between different molecular pathway within the same cells can explain the
single marker concept incompetence [90]. Additionally, histo-pathologically identical tumors might express different biological behaviors, they respond differently to treatment
and they progress at variable rates. This has been explained by the tumor heterogeneity
at different levels such as molecular heterogeneity from patient to patient, intra-tumor heterogeneity where a single tumor mass found to contain cells at different proliferation stage,
and the patient immune reaction to the tumor [104, 179]. Recent studies showed that cancer cells utilize multiple pathways to maintain their uncontrolled growth [180]. Therefore
targeting one pathway might slow down their growth but will never stop them. Therefore,
future cancer therapy should target combined pathways to arrest cancer cell growth. This
is vital in particular due to the fact that some pathways are common among different cancer types. Hence, studies showed that combined biomarker expression increased the accuracy of the prediction. For instance, CCR7 expression has been related to lymph node
metastasis prediction, however, combined CCR7, CXCR4 and HER2-neu biomarkers expression was more accurate in predicting lymph node metastasis than CCR7 expression
alone [131]. Panels of protein biomarkers typically will transcend the tumor heterogeneity
and have higher sensitivity and/or specificity for population-based screenings compared to
a single biomarker model [178]; see figure 3.2 for illustrations.

Statistical Analysis
We used machine learning algorithms to derive multivariate models that predicted
whether each sample was stage I or stage III sample. We applied two-fold cross validation to the training data (to avoid over-fitting) and used a forward-selection approach to
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Figure 3.2: ROC Curve Improvement by Multimarker Model.
The performance of A+C markers combined is better than the performance of biomarker
A alone.
Red line: marker A performance, green line: markers A+B performance, blue line: markers A+C performance.
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identify combinations of markers that were most predictive of cancer stage. Initially, we
identified individual markers that attained an area under the receiver operating characteristic curve (AUC) greater than 0.65. We then evaluated each pairwise combination of
these markers and identified combinations that attained an AUC greater than 0.70. We
continued adding one marker at a time to the model, only considering markers that increased the AUC value at each step. We used AUC thresholds of 0.75, 0.85, 0.90, and 0.95
for 3-way, 4-way, 5-way, and 6-way marker combinations, respectively. We incremented
the number of markers in our models until adding more markers no longer exceeded these
thresholds. Based on these results on the training data, we selected five marker combinations, which we further verified using the blinded samples from the testing set. We applied the following classification algorithms to the training data: Support Vector Machine
(SVM), Random Forests, k-nearest neighbors, Naive Bayes classifier, and logistic regression. [181, 182, 183]. Random Forests gave the most consistent and robust results; therefore we used this algorithm exclusively in our analysis of the testing data. For our testing
data analysis, we trained the Random Forests algorithm on the full training set and applied the resulting multimarker combinations to the full testing set. After un-blinding the
class labels, we used receiver operator characteristic (ROC) curves and AUC metrics to
assess sensitivity and specificity.

Identification of Significant Markers
The markers that showed consistent significance across the studies were further
evaluated through tandem mass spectroscopy with collision-induced energy (CID). We
took 7 µL of the sample that had high concentration of the marker to be identified, and
treated it with 3 µL 88% formic acid, then injected it into the tandem MS with different
collision energy. The fragmentation was produced by ion collisions with nitrogen or argon. The fragment patterns of every marker at different collision energy were summed for
a complete fragmentation coverage. The fragmentation spectrum was inspected visually

45

for any mis-assigned charge state. Peak charges were corrected to their +1 m/z values using the formula
+1 mass = m/z value × charge − (charge − 1H + )
The corrected charge peaks were submitted to a Mascot database search to determine the
amino acid sequence of the protein and the parent protein. Some of the markers were of
very low abundance despite serum lyophylization and therefore they did not provide an
informative fragmentation pattern.
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Figure 3.3: Pipeline Used in the Laboratory Experiments.
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CHAPTER 4: Results

Preliminary Study: Significant Biomarkers
The goal of our study is to identify novel biomarkers in human serum that would
indicate the presence of metastatic disease for patients of Breast Cancer. We used our
serum proteomics approach to analyze low abundance low molecular weight (LMW) species,
primarily peptides, in serum samples from Breast Cancer patients. The high diversity of
these species gives a high probability of identifying biomarkers whose expression is specifically associated with the presence of metastasis. In order to determine differential expression, we compared serum samples from stage I and II Breast Cancer patients with no
metastatic disease to patients with stage III disease and documented metastasis. For this
preliminary study we used commercially available samples for which there is limited patient information, but we sought to avoid samples where there was co-morbidity. Though
the serum samples in each group could not be matched perfectly, the diversity in each
group is expected to be sufficient to eliminate many biomarkers that are associated with
some unrelated trait in one group.
Serum samples were all processed simultaneously and then frozen prior to analysis
using mass spectrometry (MS) instrumentation. Each sample was then separated by reverse phase chromatography (the liquid chromatography or LC step) and subsequent MS
analysis, referred to as LC-MS. Separation of individual species in the sample is achieved
using the chromatography step, while the subsequent MS analysis provides mass information of separated species, including the relative abundance of each species. For each data
set, sample processing was performed to align species between different samples and to
determine the relative abundance of each species within that sample. Thus, the relative
abundance of individual species in each sample could be directly compared to those in all
other samples subjected to LC-MS instrumentation.
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With data generated for each sample, we then directly compared the abundance
of each species detected across all samples. Our preliminary study revealed the feasibility
of identifying candidate markers using this peptidomic approach on BC serum samples.
Interestingly, the results from this study showed also that some biomolecules could differentiate the stages of Breast Cancer. About 2500 peaks were visually examined in every
time window (total=25,000 peaks in 10 time windows), and their intensities were extracted
across all the samples. Students t-tests on the total mean normalized intensities identified
65 candidate biomarkers with statistically significant (p-value less than 0.05) differences
between stage I and III samples (Table 4.1) and another 21 biomarkers that had a nearly
significant statistical difference (0.05 < p-value < 0.10). Among the significant markers
(n=65), 9 markers were up regulated in the metastatic sera, while 56 were unexpectedly
and surprisingly down-regulated. According to the proposed stromal model by [47], freely
circulating factors (tumor-derived serum factors, or TDSFs) are released by the primary
tumor as the tumor progress. They proposed that the TDSFs levels increases with time.
Conversely, our study showed that most differentially expresses LMW peptides are down
regulated as disease progression occurs. Nonetheless, our preliminary study of small groups
reveals that proteomic analysis of highly divers and low abundance species in serum could
yield biomarkers or biomarker profiles that indicate the presence of metastatic disease in
Breast Cancer patients.

Confirmatory Study
We used data from our preliminary study to evaluate the predictive power of candidate biomarkers for detecting Breast Cancer metastasis. We procured an additional set
of 39 samples (24 used for training; and 15 used for testing) of Breast Cancer patients
with either stage I/II disease with no metastasis or with stage III disease and documented
metastasis. In order to prevent any bias in our evaluation of these samples, we had a third
party give new identification numbers to the samples, such that the patient status of each
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Table 4.1: Details of the Most Significant Markers in the Initial Study.
Markers are defined by their m/z and charge status. P-value is calculated using the markers intensities following normalization with the overall mean calculated across all the samples. Markers status describes the level of the marker as the disease progress. D: downregulated in stage III; U: upregulated in stage III.
Serial #

Marker (m/z)

Charge (z)

P-value

Marker Status

1

403.23

2

0.008

D

2

409.2

2

0.04

D

3

414.23

2

0.003

D

4

415.67

2

0.01

U

5

421.22

2

0.002

D

6

425.25

2

0.002

D

7

430.28

1

0.01

D

8

436.24

2

0.004

D

9

442.23

2

0.001

D

10

443.23

2

0.01

D

11

447.26

2

0.012

D

12

450.3

1

0.007

D

13

451.2

2

0.006

D

14

458.25

2

0.004

D

15

459.24

1

0.03

U

16

464.31

1

0.03

U

17

465.74

2

0.014

D

18

472.3

1

0.007

D

19

473.21

2

0.029

D

20

482.29

1

0.005

D

21

487.25

2

0.003

D

22

488.29

1

0.017

D

50

23

494.3

1

0.006

D

24

495.23

2

0.014

D

25

497.26

1

0.006

D

26

522.28

1

0.03

D

27

524.26

2

0.01

D

28

537.27

1

0.03

D

29

541.29

1

0.01

D

30

543.31

3

0.019

D

31

546.27

2

0.004

D

32

555.27

1

0.0002

D

33

568.27

2

0.001

D

34

571.25

1

0.0014

D

35

572.63

3

0.008

D

36

575.33

1

0.04

D

37

582.3

2

0.03

U

38

585.3

1

0.006

D

39

590.3

2

0.007

D

40

599.29

1

0.002

D

41

605.28

2

0.03

D

42

629.3

1

0.003

D

43

643.3

1

0.003

D

44

649.32

2

0.01

D

45

656.33

2

0.008

D

46

673.33

1

0.0018

D

47

687.35

1

0.002

D

48

700.36

2

0.003

D

49

709.4

1

0.02

U

51

50

713.47

1

0.02

U

51

717.35

1

0.002

D

52

721.37

2

0.005

D

53

721.42

1

0.008

U

54

722.37

2

0.002

D

55

731.37

1

0.002

D

56

743.37

2

0.02

D

57

744.3

2

0.04

U

58

747.3

1

0.02

D

59

761.37

1

0.004

D

60

792.58

1

0.019

U

61

819.43

1

0.003

D

62

835.38

1

0.005

D

63

863.43

1

0.002

D

64

879.43

1

0.015

D

65

923.45

1

0.0085

D
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samples was blinded during processing, instrumentation, and analysis. We processed all
the samples for LC-MS instrumentation in parallel and froze all samples prior to instrumentation. During LC-MS instrumentation we only detected the species that were differentially expressed in metastatic and non-metastatic groups in the preliminary study with
at least near statistical significance (p < 0.10), yielding a total of 86 species. The peaks
representing these species were aligned and the relative abundance determined to allow
comparison between each sample. Then, the differential expression between all samples
was determined. We applied the Random Forests algorithm (using a two-fold cross validation design) to the 24 training samples. Initially, using a single-marker approach, we confirmed that 12 of the 86 candidate markers provide a relatively high predictive accuracy
(AUC > 0.65; see Table 4.2). The best serum biomarker was of m/z 497.26 with an AUC
of 0.79, sensitivity of 0.79 and specificity of 0.64 as shown in Table 4.2.

Multi-Marker Model Construction
Given that individual species have limited statistical power to predict the stage
of metastasis, we sought to assess how evaluation of multiple markers in a single evaluation would improve predictive power. Using these 18 individual markers we constructed a
number of multimarker models using the Random Forests algorithm. We used a forwardselection approach as described in the methods chapter to identify marker combinations
that provided the best accuracy in the training set. In short, we randomly combined 2 or
more species together into all possible combinations and assessed how the predictive power
of the combination improved over any individual species. The best five multimarker panels
are shown in Table 4.3, with their respective AUC values.

Multi-Marker Model Validation
With partially developed multi-marker models in hand, we sought to assess their
predictive power on a set of samples that had not been previously analyzed. We procured
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Table 4.2: List of Markers that Attained an AUC > 0.65 in the Training Data Set.
425.25a is marked with * because there is another marker with m/z 425.25 but different
charge state and different elution time.
Serial #
m/z
1
497.26
2
923.45
3
761.37
4
425.25a*
5
722.37
6
585.3
7
458.25
8
747.3
9
555.27
10
442.23
11
546.27
12
879.43

Sensitivity
0.79
0.65
0.63
0.66
0.58
0.59
0.55
0.67
0.63
0.59
0.56
0.5
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Specificity
0.64
0.66
0.7
0.66
0.6
0.55
0.64
0.63
0.6
0.7
0.56
0.56

AUC
0.79
0.72
0.7
0.69
0.66
0.65
0.65
0.63
0.63
0.62
0.62
0.61

Table 4.3: Performance of the Top 5 Multimarker Models in Training Data Set.
m/z
497.26 585.3 722.37 923.45
425.25a 497.26 585.3 722.37 923.45
458.25 497.26 585.3 722.37 923.45
497.26 585.3 722.37 761.33 923.45
425.25a 497.26 585.3 722.37 761.37 923.45
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AUC
0.915
0.919
0.913
0.912
0.915

15 serum samples from the confirmatory study (the test set). We got relatively equal number of both stages (8 of stage I/II serum and 7 of stage III). The stage of the serum sample was blinded by an arbitrator who is not involved in the study. All samples were processed in parallel in the same day. They were run in the cLC-MS in a random manner.
Evaluation of the predictive power of the best 5 Multi-marker models on the 15 blinded
samples in the testing set is outlined in Table 4.4. As might be expected, accuracy levels
on the testing set were lower than were obtained with the training set. However, the multimarker models still attain accuracy levels that indicate promise for further evaluation as
predictive biomarkers in a clinical setting. For example, the best-performing model which
consisted of markers with m/z 497.26; z = +1, 458.25; z = +2, m/z 585.3; z = +1, m/z
722; z = +2 and m/z 923.45; z= +1 attained an AUC of 0.84, a sensitivity of 43% and a
specificity of 88% as shown in Figure 4.1. The box plots for each biomarker in this model
across the confirmatory dataset are plotted below (Figures 4.2–4.6). In summary, development of the multimarker models described here have been validated with a small blinded
test set and are ready for a more robust validation with a very large sample set.

Biomarker Identification
We sought to identify the species found in peaks used in the multuimarker models.
To do this, individual peaks are subjected to LC-MS under conditions where the species
is fragmented into smaller species whose individual masses are measured by the MS instrument. For peptides, fragmentation usually occurs between individual amino acids and
allow for the determination of the precise sequence. This approach is particularly challenging for low abundance species. A species that is low in abundance could by suppressed by
other species and not be picked by the instrument for fragmentation. We used a concentrated serum for those species that appear low in abundance in the sample. Furthermore,
low MW species especially those with +1 charge will provide a very short combination of
amino acid that could be shared by several parent proteins. However, they could give hints
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Table 4.4: Performance of the Top 5 Multimarker Models in Testing Data Set.
m/z
497.26, 585.3, 722.37, 923.45
425.25a, 497.26, 585.3, 722.37, 923.45
458.25, 497.26, 585.3, 722.37, 923.45
497.26, 585.3, 722.37, 761.37, 923.45
425.25a, 497.26, 585.3, 722.37, 761.33, 923.45
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AUC
0.84
0.76
0.804
0.77
0.77

Figure 4.1: Performance of the Top 5 Multimarker Models in Testing Data Set.
M: Metastatic, P: Pre-metastatic.
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Figure 4.2: Box Plot of Biomarker with m/z 497.26

59

Figure 4.3: Box Plot of Biomarker with m/z 458.25
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Figure 4.4: Box Plot of Biomarker with m/z 585.28
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Figure 4.5: Box Plot of Biomarker with m/z 722.37
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Figure 4.6: Box Plot of Biomarker with m/z 923.45
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to the identity of the parent protein and therefore exclude other possibilities. Most of the
biomarkers that built the multimarkers models were having an adjacent overlapped peak.
Therefore, the fragmentation pattern of these biomarkers might contain fragments of both
peaks that were hard for the system to distinguish. We tried to fragment the biomarker
m/z 497.26 which was showing a consistent significance across the initial and confirmatory
data set. Its mass spectrum is showing a overlapped peak with m/z 497.24 (Figure 4.7).
Surprisingly, its fragmentation profile did not appear to be consistent with the
species being a peptide because there was no evidence of immonium ions and no fragments
occurred at intervals consistent with amino acids, with or without modifications. Instead,
the fragmentation spectrum of this biomarker was consistent with choline containing lipid
species, primarily due to the presence of a high abundant peak at m/z 184.07 that indicates the presence of a phosphocholine head group. We tried to fragment this biomarker
with collision energies that range from 15 to 35 V and we noticed that the fragmentation
spectrum of this particular species yielded a consistent fragmentation profiles with different intensities. In addition, the m/z 184.07 fragment was always observed as the collision
energy changed. In general, the fragmentation profile of phosphocholine lipid species such
as phosphatidylcholine (PC) , sphyngomyeline (SM) and lyso PC display the product ion
with either m/z 59, 104 or 184 corresponding to trimethylamine, choline and phosphocholine moieties, respectively. The m/z 104 and m/z 184 fragments are displayed in the
m/z 497.27 fragmentation spectra (Figure 4.8). The complete structure of the phosphocholine species could not be determined but the nitrogen rule can suggest what species
it is. The nitrogen rule states that, if M+ H+ has an even m/z (i.e., having odd neutral
mass), then it should correspond to the presence of odd number of nitrogen atoms. Conversely, if M+ H+ has an odd m/z (i.e., having even neutral mass) then it should represent even numbered nitrogen atom containing species. In other words, protonated PC
molecules appear at even m/z values, whereas protonated molecules of SM exhibit odd
m/z values. This is due to the presence of an additional nitrogen atom in SM. The appli-
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Figure 4.7: Overlapping Peaks at m/z 497.27.
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cation of this rule suggests that 497.27 is a SM species of lipid. Further supporting this,
we observed a peak of m/z 69 that is indicative of sphyngomyelin lipid group. Taken together, this biomarker fragmentation profile indicates that this critical biomarker is a SM
lipid species. Alternately, the consistent presence of the fragment with m/z 479 indicates
water loss is occurring in this molecule. Therefore, this SM species could be oxidated.
On the other hand, the product ion at m/z 147 corresponds to sodiated five-member cyclophosphane [184], which is displayed in the m/z 497.27 fragmentation spectra. Therefore,
this biomarker could also be a sodiated SM. In fact, fragment ion of m/z 147 has been
seen in the fragmentation profile of non-sodiated SM, which results from some overlap.
Despite the ability to identify this molecule as an oxidated SM, we can not be sure
that it is corresponding to m/z 497.27 because of the co-eluting peak with m/z 497.24
that is more prominent as shown in Figure 4.7. Unfortunately, all the other biomarkers
that built the multimarker model were having an overlapping peak that is interfering with
the fragmentation profile of the biomarker of interest (Figures 4.9–4.13). Therefore, they
did not yield interpretable MS/MS fragmentation spectra. There are several factors contributed to the difficulty in identifying these other biomarkers using the fragmentation approach. The use of the microcapillary column for peptide separation, which is packed with
POROS R1 slurry of 10 µm particle size could be one of the main factor because it gave
wide peaks and overlapped spectra. Other factors that could be responsible for the low
resolution will be discussed in the discussion.
We tried a new run where we changed the flow rate in the experiment from 5.0
µL/min to 10 µL/min and we were able to get a better resolution for the biomarker with
m/z 761.38. Fragmentation of this biomarkers was possible because of the absence of coeluting peaks.
The fragmentation profile of the marker with m/z 761.38 was showing immonium
ions of some amino acids. Through scanning of the fragmentation profile we could see
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Figure 4.8: The Fragmentation Spectra of Biomarker with m/z
497.27.
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some mass differences that correspond to the mass of amino acids and the proposed sequence is DLVPGNF, see Figure 4.14.
Doing a blast search for this sequence showed some suggested proteins that have
DLVPGNF partial sequence. Using Fragment Ion Formula Calculator, we got a list of expected b and y ions series that should be seen in the ms/ms spectra of m/z 761.38 according to the proposed protein. It turned out to be a fibrinogen alpha chain (FAC) isomer 2
as the proposed b and y ions corresponding to the FAC by Fragment ion formula calculator were all present in the m/z 761.38 fragmentation profile, see Figure 4.15.
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Figure 4.9: Overlapping Peaks at m/z 425.25

69

Figure 4.10: Overlapping Peaks at m/z 458.25
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Figure 4.11: Overlapping Peaks at m/z 923.45
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Figure 4.12: Overlapping Peaks at m/z 722.37
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Figure 4.13: Overlapping Peaks at m/z 761.38
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Figure 4.14: Ms/Ms of m/z 761.38
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Figure 4.15: Fragment Ion Calculator Result
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CHAPTER 5: Discussion

The advancement in early Breast Cancer detection led to a 16% increase in early
diagnoses, while the mortality rate of BC remained unchanged [5]. Metastasis is the main
cause of death among Breast Cancer patients. Therefore, determining the tumor potential
to spread before the onset of metastasis will pave the road toward personalized therapy
and save many patient from being overtreated and improve their quality of life [185].
Breast Cancer metastasis is currently monitored by radiological imaging that suffers from detection limitations [9]. While tumor metastatic potential is largely determined
by evaluating the tumor size, grade and involvement of regional lymph nodes, molecular
biomarkers are currently used in this evaluation. The complementary effect of the biological markers such as estrogen and progesterone hormone receptors, HER-2, and plasminogen activator inhibitor 1 should not be underestimated [9, 18]. It is worth mentioning that
all of these prognostic factors rely on tissue specimens from primary or secondary site, obtained either by biopsy or surgical resection. Therefore, they can not by definition be used
for a inexpensive, reproducible and noninvasive screening assay [186]. Ca 15-3 and CEA
are the two serum markers that are widely used to predict recurrence and metastatic potential of breast, ovarian, and uterine cancers. [18]. These serum markers suffer from low
sensitivity and specificity that necessitates the search for a more powerful prognostic and
metastasis predictive approach [187]. There is a soaring need for more robust markers that
have diagnostic and predictive power across Breast Cancer subtypes [11] and circulating
markers are more clinically desirable [188].
The rapid advancement of high throughput proteomics in recent decades have not
uncovered any novel serum biomarkers that can displace currently used tissue or replace
existing low-predictive serum markers. This is a result of the inherent limitation of the
conventional ‘bottom-up’ approach and the complexity of human serum. In addition, subtypes and subpopulation heterogeneities of tumors complicates markers discovery, which
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could be overcome by combining markers, as proposed by some researchers [189]. Our goal
was to evaluate the applicability of a proteomic approach in BC serum samples and its
quantitative power to differentiate between metastatic and non-metastatic Breast Cancer. The proteomic approach we have applied in this project showed success in previous
studies done on preterm birth [190], preeclampsia [173, 191] and Alzheimer’s disease [192].
The uniqueness of this approach is its capability to detect biomarkers from an array of low
abundance but highly divers species found in different human biospecimens. This study
demonstrated that this ‘top-down’ approach is effective in identifying differentially expressed biomarkers from low abundance low molecular weight (LMW) molecules in serum.
We were able to detect biomolecules in serum samples that significantly differentiate between the two serum sample groups. Surprisingly, the majority of identified molecules
were down-regulated in stage III sera, rather than upregaultes, as expected. Previously
identified circulating peptides were mostly up-regulated with disease progression. Lv et.
al. studied the role of circulating cytokine in BC metastasis and found multiple cytokines
that are positively associated with BC progression. However, they also found two serum
cytokines, MCP-1 and IP- 10, that were down-regulated with disease progression. Their
decreased expression levels were significantly and inversely correlated with patients who
had more positive lymph nodes[148].

Downregulated Metastatic Biomolecules Identified in Virto
There are other peptides that are found to be downregulated in BC tissues and cell
lines studies. For example, RAB1B expression was low in highly metastatic cells and could
be considered as a metastasis suppressor in triple negative BC (TNBC) [137]. In another
study, the migration and invasion of a highly metastatic BC cell line were dramatically
reduced by RhoGDIα upregulation [138]. Furthermore, CD59 and CSPG4 were found
to be inversely correlated with BC metastasis [141]. Li et. al. looked at the BC cell line
secretome using a bottom up approach and all the identified peptides were upregulated
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in the metastatic cell line secretome compared to the non-metastatic ones. Mesothelin
(MSLN) was the only peptide found to be inversely correlated with tumor aggressiveness
[11]. LIFR is an example of a metastatic suppressor that is found to be down-regulated
in Breast Cancer tissue [193]. As an alternate theory to explain the large number of peptides whose expression is down-regulated in metastatic patients, perhaps the presence
of metastatic cells results in the depletion of specific peptides and proteins from serum.
Torosian detected some circulating peptides that were suppressing tumor metastasis which
could not be synthesized by tumor-bearing animals on protein depleted diet due to absence of amino acids subunits [194].

Metastatic Suppressors
Metastasis suppressors are molecules that prevent the dissemination and growth
of tumor cells in the secondary organ but has no or minimal effect on the primary tumor
[195]. The first identified metastatic suppressor was Nm23 where it provided functional
evidence for the existence of specific genes that control metastasis [32]. Today, more than
thirty metastasis suppressors have been identified [196] that vary widely in term of cellular localization where some are produced intracellular and some are in the extracellular
matrix. They vary in their mechanism of action, some promote cell-to-cell adhesion that
will slow cell migration out of the primary tumor such as E-cadherin. Other metastasis
suppressors act by inhibiting cell motility and invasion such as Nm23, tissue inhibitors of
metalloproteinases (TIMP), SseCKS, caspase-8, BRMS1, KAI1 inhibit metastasis by reducing cells survival while they are in the way toward the secondary site. KISS1, MKK4,
p38, MKK7 act on the disseminated cells at the secondary site to prevent their proliferation [196, 195, 197, 198].
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Metastatic Suppressor Genes
It is likely that the discovered metastatic suppressor genes did not provide a complete understanding of the mechanism of metastatic and its suppression [197]. That is because the protein products of these genes varies and each will have a different mechanism
of action. For example, serum kisspeptin levels (product of metastatic suppressor gene
KISS1) were significantly lower in the infertile male compared to fertile male who have
no malignancy [199]. Therefore, identifying metastatic suppressor proteins will be more
functional and applicable. Since the downregulated biomarkers that we detected were associated with invasive stage of BC, further understanding of their identities, origin, and fate
during cancer progression is clearly needed.

Peak Overlapping in Mass Spectroscopy
Mass spectroscopy based serum proteomic studies are prone to show ion suppression due to the variation of the serum peptide MW despite the use of acetonitrile precipitation. Isobaric species tend to co-elute and provide a convoluted mass spectrum. This
could affect the quantitation of the co-eluted species and more importantly interfere with
fragmentation profile of the peak of interest because the eluted peaks will be fragmented
together. The identification of the biomarker that built the multimarker model was challenging because of the existence of overlapping peaks. Several technical parameters of the
chromatographic methods could contribute to these findings which can be summarized in
the resolution equation

Rs = 1/4 [k/(1 + k)] (1 − α) (N )1/2

where Rs is the resolution of two closely eluting peaks, k represents retention; α
is the ratio of the retention for closely eluting peaks; and N represent column efficiency
(plate number). These three parameters need to be adjusted in order to get a better peak
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spacing. For example, increasing column efficiency could solve moderately overlapped
peaks. Column efficiency could be enhanced by increasing the column plate number that
is a achieved by increasing the column length or the use of smaller particles. Columns with
smaller particle sizes results in a higher plate numbers which subsequently give sharper
peaks. The size of the particles also depends on the size of the studied molecules because
large MW species dont show a good separation in the small pore size packings [200]. Due
to financial constraints, we could not replace the column we implemented in our studies
with a longer column or using different packings. Another way to improve column efficiency is to elevate column temperature. Higher column temperatures lead to reduce mobile phase viscosity that subsequently increase column efficiency due to increase solvent
diffusion [200]. Since we are dealing with proteins which are thermolabile, increasing column temperature might degrade them.
Changing the strength of the mobile phase has been found to solve minor overlaps.
What could be seen in our mass spectra is that we have major overlap that would be unlikely to be solved by this intervention. Additionally, it has been shown that changing the
mobile phase will not help to solve the co-elution if the sample has a large number of components or if the co-eluted peaks are isomers that crowd the chromatograph which is the
case with human serum samples that we study [201]. In fact, we did several runs with different mobile phase gradient and were unlucky getting the overlap solved.
Flow rate is another factor that could exert a change in the peak signals as increasing the flow rate results in large signals and therefore a greater amount of sample mass is
reaching the instrument per unit. We noticed biomarker m/z 761.38 was represented with
a very clear peak when we increased the flow rate from 5 µL/minutes to 10 µL/minutes.

Sphingomyelin Species are Potential Biomarkers for Cancer
It is worth mentioning here that the fragmentation of one of the best markers in
our study was somehow consistent with oxidated sphingomyelin (SM). SM is a polar lipid
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which is composed of an alcohol portion (sphingosine), a long-chain fatty acid that is connected by an amide bond to the amino group and a phosphorylcholine head group. The
combination of a fatty acid and sphingosine is called ceramide, see Figure 5.1.
Sphingomyelins are one of the major membrane phospholipids that are mainly localized to the outer leaflet of the plasma membrane. Several studies link SM to multiple cellular pathways such as cell migration, cell proliferation, apoptosis, autophagy and
growth arrest [202]. In fact and to be more specific, it is SM metabolites, such as sphingosine, sphingosine 1-phosphate (S1P), and ceramide, that control these pathways. Ceramide
has a pro-apoptotic property while S1P has anti-apoptotic property and it induces cell
proliferation and growth [184]. The dynamic balance between these two SM metabolites
usually determines cell behavior.
Cancer cells exhibit altered metabolic activity that aims to maintain the rapid
proliferation of cancer cells [203]. SM is one of the lipids that is highly involved in cancer development and progression. SM levels are found to be significantly higher in highly
metastatic cancer cells compared to those in less metastatic cells [204]. Unexpectedly, in
our study, we found that this specific SM lipid is down-regulated in metastatic serum samples. We propose four possible explanations for the reduction of serum SM in the metastatic
stage: 1) the up-regulation of Ceramide SM metabolites, 2) up-regulation of sphingosine1-phosphate SM metabolites, 3) the high prevalence of lipid rafts in cancer and 4) the production of extracellular membrane vesicles from tumor cells.

Upregulation of Ceramide in Cancer
Ceramide is a sphingolipid with sphingosine backbone that is generated de novo by
condensation of serine and palmitoyl-CoA or through hydrolysis of sphingomyelin by sphingomyelinases, known as the “sphingomyelin cycle”. Ceramide is a pro-apoptotic molecule;
it induces cell death and arrests growth. Doria et al. found that regular intake of SM was
associated with a reduction in colon cancer in animals [205]. Researchers proposed that
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Figure 5.1: Chemical Structure of Sphingomyelin.
SM is comprised of sphingosine backbone (mainly C-18). (A) A long chain fatty acid attached to sphingosine through amide linkage forms ceramide. (B) SM is produced by replacement of hydrogen group of ceramide (H*) with various functional head groups phosphocholine in (C) and phosphor-ethanolamine in (D).
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one possible mechanism for this inhibition is through the generation of ceramide from SM
hydrolysis, which will exert an apoptotic effect on colon cancer cells [206].
Several studies revealed high expression of different species of ceramide in different cancers, such as nodal positive pancreatic cancer, squamous cell carcinoma of the head
and neck, BC and prostate cancer. Theoretically, ceramide should be down-regulated in
cancer [206]. The up-regulation of ceramide was explained by the presence of several distinct species of ceramides, which differ according to length of fatty acid chain, saturation
level, and sites of double bonds. Different ceramide species also differ in their functionality.
For example, the accumulation of C16-ceramides found to have a proliferative properties
whereas C18-ceramides have apoptotic/growth arresting properties. Thus, up-regulation
of some ceramides could be associated with cancer progression. The generation of such
species necessitates increased SM hydrolysis, which could explain low levels of serum SM
in metastatic patients.

Upregulation of Sphingosine-1-phosphate (S1P)
S1P is produced by phosphorylation of sphingosine by sphingosine kinases, see Figure 5.2. It can be produced either in the inner part of the plasma membrane and then
transported elsewhere or in the plasma. Plasma production may occur by either the same
biochemical steps as occur in the membranes of cells [207] or by the hydrolysis of sphingosylphosphorylcholine by the enzyme autotaxin [208]. S1P is well known to induce cell migration, proliferation, invasion, and angiogenesis [209, 210]. Analysis of plasma from nodal
positive pancreatic cancer patients reveals high expression of S1P compared to nodal negative pancreatic cancer patients [211]. Additionally, it is up-regulated in BC and is associated with poor prognosis and resistance to chemotherapy [212]. Further, Ogretmen
et. al. found that disseminated cancer cells into the blood stream induce the elevation
of serum S1P. They found that systemic S1P generated in circulation, but not primary
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tumor-derived S1P, controls cancer metastasis. Clearly serum SM is utilized extensively in
order to produce more S1P, which in turn drives cell proliferation and migration.

Lipid Raft-associated SM
Lipid rafts are specialized cholesterol-enriched microdomains of the plasma membrane that are formed by the assembly of cholesterol, sphingolipids and certain types of
proteins. They have been implicated to play a role in different cellular pathways needed
for cell survival, proliferation, and migration [213, 214, 215, 216]. The composition of lipid
rafts differs from that of the surrounding bilayer membrane. Studies show that they contain 3-5 fold more cholesterol than the plasma membrane. The sphingomyelin content of
the lipid raft is 50% more than that of the adjacent part of the plasma membrane. Since
rapidly proliferating tumor cells have more rafts and require cholesterol for new membrane
synthesis, their need for SM and cholesterol is highly elevated [213]. In fact, researchers
found that patients with advanced cancer have hypocholesterolemia that is associated with
hyposphingomyelinemia [217].

Extracellular Membrane Vesicles from Tumor Cells (EMVTCs)
Studies showed that the level of extracellular membrane vesicles are elevated by five
times in cancer patients compared to levels in normal patients [218]. Their number in the
blood is positively correlated to the invasiveness of the tumor [219, 220]. EMVTCs are believed to have angiogenic activity, which can promote the growth of disseminated cancer
cells. These EMVTCs are enriched with SM, which is considered the active component
that stimulates angiogenesis. As the tumor progress, angiogenesis increases and could deplete the plasma of EMVTCs that contain SM. It is worth mentioning that cancer tissues
need more cholesterol and SM than they are capable of generating by their own lipid synthesis pathways. In fact adipocytes were found to enhance cancer cell migration and invasion through the continuous supply of lipids, which cancer cells use for structural assembly
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and energy for rapid growth [221]. Several studies showed that cancer mortality increases
if the patient has low plasma cholesterol [222]. Whether low cholesterol drives cancer aggressiveness or the progression of cancer results in low plasma cholesterol is unclear and
needs further study.

Oxydated Sphingomyelin in Cancer
It is well known that cancer cells experience a metabolic shift from oxidative phosphorylation to aerobic glycolysis, which is known as Warburg effect [223]. They use different metabolic pathways to meet their increased energy demands. Lipid metabolism is a
vital source of energy for cancer cells and results in changes in lipid synthesis, lipid degradation and catabolism, and fatty acid (FA) oxidation [224]. It has been estimated that almost all tumors will gain lipogenesis capability, meaning cancer cell are able to the synthesize fatty acids de novo in a rate comparable to liver cells. The increase in FA oxidization
in cancer cells could explain the detection of oxidated SM in the serum of BC patients.
Despite the evidence linking SM to cancer initiation and progression, it is too early
to speculate as to the physiological significance of downregulation of circulating SM species
as a predictor of tumor progression. However, coupling this marker with other clinicopathological parameters might increase the predictive power of these combined markers.

Fibrinogen Physiological Function
The fragmentation profile of the biomarker with m/z 761.38 was consistent with
fibrinogen α chain (FAC). FAC is one of the chains that build up fibrinogen molecule.
Fibrinogen is a plasma protein produced by hepatocyte with a molecular weight of 340kDa. It consists of two pairs of three polypeptide chains α, β, and γ that are connected by
disulfide bonds. It is involved in the last phase of the coagulation process. It circulates in
the blood in insoluble form and need to be activated into its active form by the protease
thrombin. Thrombin cleaves four specific Arg-Gly bonds at the N termini of both the α
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Figure 5.2: Sphingomyeline Hydrolysis.
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and β chains, releasing fibrinopeptides A (FpA) and B (FpB) respectively, see Figure 5.3
[225]. These cleavages result in further arrangement of the molecule chains forming a network of fibres that stabilise the clot [226]. In fibrinolysis, fibrin will be cleaved by plasmin
at two different sites to break down the clot. Fig 5.4 shows the cleavage sites of FAC by
the three enzymes: thrombin, plasmin and hementin that are involved in coagulation process.

Fibrinogen and Fibrin in Metastasis
The relationship between tumor metastasis and coagulation process has been widely
studied. Fibrin and fibrinogen in particular gained more focused interest. Cleavages of fibrinogen and fibrin yield various products that have been found to regulate several critical
cellular pathways and functions such as chemotachtic activities, cell adhesion and vasoconstriction. For example, fibrin A (a cleavage product of fibrin clot formation), fibrinopeptide A and fibrinogen α found to be associated with the initiation of multiple solid tumor
[227, 228]. Furthermore, Fibrinogen/fibrin have been found to play a role in tumor progression. Collectively, studies found that fibrin and fibrinogen products enhance tumor
progression through three proposed mechanisms, inducing angiogenesis, protecting the tumour cells from the natural killer cell and serving as a bridging molecule between tumor
cells and the surrounding micro-environment [229]. Studies found that breast cancer, lung
carcinoma and malignant melanoma metastasis but not primary tumor growth was significantly reduced in fibrinogen deficient mice [230]. These findings suggest that therapy
targeting the fibrinogen system might prevent or treat metastasis. In fact recent studies
showed that anticoagulant therapy resulted in diminished metastasis and improved cancer
outcome [229]. We found a decrease in the serum level of a fragment of fibrinogen α chain
in the metastatic group. This fragment is not related to physiological cleavages of fibrinogen α chain by any of the enzymes thrombin, plasmin and hementin that are involved in
coagulation, see Figure 5.4. There might be another break down mechanism of fibrinogen
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α chain that release such fragment in malignency. Further studies are needed to understand the mechanism and regulation of the reduction of this fibrinogen α chain fragment
in metastatic breast cancer.

Limitations
Potential pitfalls usually exist in any scientific approach and we faced several challenges which accounted for a number of limitations in this project. Starting with the design of our study and due to financial constraints, we used small numbers of samples in
each experimental group. In our preliminary study, in which we identified initial peaks and
validated the approach for use in differentiating between metastatic and non-metastatic
patients, we only used 6 samples of stage I and 6 samples of stage III BC. The use of small
numbers of samples reduces the ability to identify highly predictive biomarkers or biomarker
profiles. Further complicating this issue is the fact that serum samples are considered a
major source of false discovery despite the fact that they are more attractive for biomarkers studies. Variability in serum samples exists at different levels of collection and storage.
Standardization of collection techniques, handling and storage will eliminate the non biological quantitative differences. We tried to confirm this with both companies for both
samples sets. One of the inevitable factors is that these samples are collected at different
phase of the tumor development and collected at different clinic visit so they reflect different points along the the course of the tumor development. We tried to get the best matching sample sets in every study, but we could not get the full details of each patients such
as menopause, genetic subtypes and stage of treatment. All these factors make it very
challenging to label an identified protein as BC specific marker that is produced by tumor
secreted protease. They will need further validation studies that follow a rigorous sample
collection protocols and using different methodology.
The subsequent validation of the preliminary biomarkers in a set of blinded and
independent serum samples (our confirmatory study with 39 total samples) showed the
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Figure 5.3: Primary Structure of the Fibrinogen Chains up to the
First Disulphide Bond.
Shaded sequence: thrombin binding site, sequence with bold
characters: fibrinopeptide A and B
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Figure 5.4: Full Length Sequence of Fibrinogen Alpha Chain.
Yellow: Thrombin cleavage site to release fibrinopeptide A.
Green: Plasmin cleavage site to break down fibrin clot.
Red: Hementin cleavage site to prevent coagulation.
Blue: Sequence of novel fragment (m/z 761.38).
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potential significance of some of these biomarkers. The ability to replicate results in a
blinded test set suggests that the use of best multimarker models could differentiate between samples based on the metastatic status and not based on artifacts of processing or
on other confounding factors.
An additional issue comes from biomarker quantitation. Several factors should be
considered that might contribute to the quantitative difference in proteins levels in any
clinical samples [231]. Cancer heterogeneity and clinical samples variabilities are the two
main critical and contributing factors that should be considered [231]. Breast cancer in
particular is among the most heterogeneous cancer types. There is a complex heterogeneity at the inter- and intra-tumor levels. It is hard to predict that the same type of BC will
have the same alteration in protein level. Furthermore, proteins undergo cancer specific
posttranslational modification that are reflective of the tumor cells physiology and might
interfere with analysis and identification of detected serum markers [232].
Additionally, the approach we used in this study was mainly built for the study
of low M.W. peptides in biospecimens. However, the tandem MS studies that were designed to identify the potential biomarkers revealed that there are lipids components ( m/z
497.27). The protocol calls for normalization of biomarker levels across all samples, but
uses a bicinchoninic acid (BCA) protein assay that quantitates protein levels but does not
detect lipids. Therefore, it is uncertain if the amount of each sample loaded into the MS
was normalized for lipid levels. It will only become accurate if the levels of lipids relative
to protein were constant.
Furthermore, the mass spectrum of the samples regularly showed overlapping or
wide peaks. This can be explained by effects from the microcapillary column that we used
for peptide separation, which is packed with POROS R1 slurry of 10 µm particle size.
This effect results in difficulty in the identification of most of the biomarkers which have
an overlapping peak adjacent to them. Therefore, their fragmentation spectrum included
fragments from the overlapping peaks as well, making conclusions from the post collision
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spectrum very challenging. For example, the fragmentation spectrum of biomarker m/z
497.27 displayed a product ion at m/z 184.06 that indicates a phosphocholine group, but
this peak could be a fragmentation product of either the peak of interest or to the overlapping peak with equal probability.
Another challenge we faced is in lipid identification. Despite that the presence of a
polar group that could hint at the lipid class, the complete structure of the identified lipid
class could not be determined. Available databases, such as lipid map, do not not provide
fragmentation data for comparison with fragmentation spectra generated from our experiment. Instead it only provides list of matches according to the accurate m/z. Therefore,
further challenging lipid identification is the lack of a lipid database that includes any oxidized lipids.
One of the most challenging and tedious part of our study is the data analysis,
which was performed manually. The output of LC-MS/MS of serum is very complicated,
commonly has overlaps, and ion suppression must be accounted for during the visual analysis. The size of the file from one sample spectra is between 1 to 5 GB (2500 peaks in 10
time windows = 25000 total peaks), which makes it a tedious job in the absence of an automated software. Though we tried several software programs for automated analysis, it
missed almost 80% of the potential biomarker that were detected manually. Technically,
the development of computer programs that could allow faster and accurate data analysis will increase the efficiency and productiveness of analyzing many more samples within
reasonable time. Efforts could be made in this direction in the future in developing software that can discriminate peaks, compare them and calculate the statistical differences
between cases and controls automatically.

Future Research
In this study we were able to partially identify two of the low molecular weight
serum biomarker for Breast Cancer that were detected through protoemics-based approach.
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Further work focusing on identifying other biomolecules that are consistently present in
our high performing multimarker models, such as m/z 458.25, 722.37, 923.45 and m/z
425.25, will be valuable. In addition, running an MS/MS experiment to fragment the marker
m/z 497.27 at different chromatographic parameters to separate it from the co-eluting
peaks would help to figure out if a reduction in serum SM could reflect the stage of Breast
Cancer. It would also be very interesting to evaluate the performance of the detected markers in stage IV (distant metastatic) Breast Cancer sera. This will provide more details on
the role of these molecules in distant metastasis and if cancer cell use different metabolites for their distant colonization. The proteomic evaluation of the changes in circulating molecules from stage I to stage II, stage III and stage IV could uncover the ongoing
metabolism in the progression of the Breast Cancer.
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Budinská, Rostislav Vyzula, Spiros D Garbis, Boivoj Vojtěšek, and Rudolf Nenutil.
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[156] Ning Qing Liu, Christoph Stingl, Maxime P Look, Marcel Smid, René B H Braakman, Tommaso De Marchi, Anieta M Sieuwerts, Paul N Span, Fred C G J Sweep,
Barbro K Linderholm, Anita Mangia, Angelo Paradiso, Luc Y Dirix, Steven J Van
Laere, Theo M Luider, John W M Martens, John A Foekens, and Arzu Umar. Comparative proteome analysis revealing an 11-protein signature for aggressive triplenegative breast cancer. Journal of the National Cancer Institute, 106(2):djt376, feb
2014.
[157] Yan Cui, Ming Niu, Xianyu Zhang, Zhenbin Zhong, Ji Wang, and Da Pang. High expression of valosin-containing protein predicts poor prognosis in patients with breast
carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36(12):9919–27, dec 2015.
[158] Guiyang Jiang, Xiupeng Zhang, Yong Zhang, Liang Wang, Chuifeng Fan, Hongtao
Xu, Yuan Miao, and Enhua Wang. A novel biomarker C6orf106 promotes the malignant progression of breast cancer. Tumour biology : the journal of the International
Society for Oncodevelopmental Biology and Medicine, 36(10):7881–9, sep 2015.
[159] Hyojin Kim, Kyung-Hun Lee, In Ae Park, Yul Ri Chung, Seock-Ah Im, Dong-Young
Noh, Wonshik Han, Hyeong-Gon Moon, Yoon Yang Jung, and Han Suk Ryu. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Archiv : an international journal of pathology, 467(5):563–70, nov 2015.
[160] Haihong Pu, Qingyuan Zhang, Chunbo Zhao, Lei Shi, Yan Wang, Jingxuan Wang,
and Minghui Zhang. Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma.
World journal of surgical oncology, 13:323, jan 2015.
108

[161] Yanjie You, Haijun Li, Xin Qin, Yinpo Zhang, Wengang Song, Yonggang Ran, and
Fenglan Gao. Decreased CDK10 expression correlates with lymph node metastasis
and predicts poor outcome in breast cancer patients - a short report. Cellular Oncology, 38(6):485–491, dec 2015.
[162] Purevdorj B Olkhanud, Dolgor Baatar, Monica Bodogai, Fran Hakim, Ronald Gress,
Robin L Anderson, Jie Deng, Mai Xu, Susanne Briest, and Arya Biragyn. Breast
cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer research, 69(14):5996–6004, jul 2009.
[163] Kyle Strimbu and Jorge A Tavel. What are biomarkers? Current opinion in HIV
and AIDS, 5(6):463–466, nov 2010.
[164] Shen Hu, Joseph A Loo, and David T Wong. Human body fluid proteome analysis.
Proteomics, 6(23):6326–6353, 2006.
[165] Alessandra Tessitore, Agata Gaggiano, Germana Cicciarelli, Daniela Verzella, Daria
Capece, Mariafausta Fischietti, Francesca Zazzeroni, and Edoardo Alesse. Serum
biomarkers identification by mass spectrometry in high-mortality tumors., 2013.
[166] Glen L. Hortin, Saeed A. Jortani, James C. Ritchie, Roland Valdes, and Daniel W.
Chan. Proteomics: A new diagnostic frontier. Clinical Chemistry, 52(7):1218–1222,
jul 2006.
[167] Serena Camerini, Maria Letizia Polci, Lance A Liotta, Emanuel F Petricoin, and
Weidong Zhou. A method for the selective isolation and enrichment of carrier
protein-bound low-molecular weight proteins and peptides in the blood. Proteomics.
Clinical applications, 1(2):176–84, feb 2007.
[168] Eduard Orvisky, Steven K Drake, Brian M Martin, Mohamed Abdel-Hamid,
Habtom W Ressom, Rency S Varghese, Yanming An, Daniel Saha, Glen L Hortin,
Christopher A Loffredo, and Radoslav Goldman. Enrichment of low molecular
weight fraction of serum for MS analysis of peptides associated with hepatocellular
carcinoma. Proteomics, 6(9):2895–902, may 2006.
[169] L Guerrier, L Lomas, and E Boschetti. A simplified monobuffer multidimensional
chromatography for high-throughput proteome fractionation. Journal of chromatography. A, 1073(1-2):25–33, may 2005.
[170] Luc Guerrier, Frederic Fortis, and Egisto Boschetti. Solid-phase fractionation strategies applied to proteomics investigations. Methods in molecular biology (Clifton,
N.J.), 818:11–33, jan 2012.
[171] Karin Björhall, Tasso Miliotis, and Pia Davidsson. Comparison of different depletion
strategies for improved resolution in proteomic analysis of human serum samples.
Proteomics, 5(1):307–17, jan 2005.

109

[172] R J Leatherbarrow and P D Dean. Studies on the mechanism of binding of serum
albumins to immobilized cibacron blue F3G A. The Biochemical journal, 189(1):27–
34, jul 1980.
[173] Swati Anand, Tanielle Mei Bench Alvarez, W Evan Johnson, M Sean Esplin, Karen
Merrell, T Flint Porter, and Steven W Graves. Serum biomarkers predictive of preeclampsia. Biomarkers in medicine, 9(6):563–75, jan 2015.
[174] Wei-Jun Qian, Jon M Jacobs, Tao Liu, David G Camp, and Richard D Smith.
Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Molecular & cellular proteomics : MCP,
5(10):1727–44, oct 2006.
[175] Jeffrey T Leek, Robert B Scharpf, Héctor Corrada Bravo, David Simcha, Benjamin
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The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer research, 18(5A):3433–7, jan.
[221] Wael Al-Zoughbi, Wael Al-Zhoughbi, Jianfeng Huang, Ganapathy S Paramasivan,
Holger Till, Martin Pichler, Barbara Guertl-Lackner, and Gerald Hoefler. Tumor
macroenvironment and metabolism. Seminars in oncology, 41(2):281–95, apr 2014.
[222] Sandeep A Bailwad, Navneet Singh, Dhaval R Jani, Prashant Patil, Manas Singh,
Gagan Deep, and Simranjit Singh. Alterations in serum lipid profile patterns in oral
cancer: correlation with histological grading and tobacco abuse. Oral Health Dent
Manag, 13:573–579, 2014.
[223] O. Warburg. On the Origin of Cancer Cells. Science, 123(3191):309–314, feb 1956.
[224] Yoon Yang Jung, Hye Min Kim, and Ja Seung Koo. Expression of Lipid
Metabolism-Related Proteins in Metastatic Breast Cancer. PloS one, 10(9):e0137204,
jan 2015.
[225] C G Binnie and S T Lord. The fibrinogen sequences that interact with thrombin.
Blood, 81(12):3186–3192, 1993.
[226] J L Mullin, O V Gorkun, C G Binnie, and S T Lord. Recombinant fibrinogen studies
reveal that thrombin specificity dictates order of fibrinopeptide release. The Journal
of biological chemistry, 275(33):25239–46, aug 2000.
[227] Annemieke W J Opstal-van Winden, Esmeralda J M Krop, Monica H Kåredal,
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